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Summary 25 
 26 
Phenotypic screens for bactericidal compounds against drug-resistant 27 
tuberculosis are beginning to yield novel inhibitors. However, reliable target 28 
identification remains challenging. Here we show that tetrahydropyrazo[1,5-29 
a]pyrimidine-3-carboxamide (THPP) selectively pulls down EchA6 in a 30 
stereospecific manner, instead of the previously assigned target M. tuberculosis 31 
MmpL3. While homologous to mammalian enoyl-CoA hydratases, EchA6 is non-32 
catalytic yet essential, and binds long-chain acyl-CoAs. THPP inhibitors compete 33 
with CoA-binding, suppress mycolic acid synthesis and are bactericidal in a 34 
mouse model of chronic tuberculosis infection. A point mutation, W133A, 35 
abrogated THPP-binding and increased both the in vitro minimum inhibitory 36 
concentration and the in vivo effective-dose 99 in mice. Surprisingly, EchA6 37 
interacts with selected enzymes of fatty acid synthase II (FAS-II) in bacterial 38 
two-hybrid assays, suggesting essentiality may be linked to feeding long-chain 39 
fatty acids to FAS-II. Finally, our data show that spontaneous resistance-40 
conferring mutations can potentially obscure the actual target or alternative 41 
targets of small molecule inhibitors.  42 
43 
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Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), is a global 43 
disease with an estimated 8.7 million new cases and around 1.4 million deaths 44 
annually1. TB drug-resistance first emerged 40 years ago, but since then has grown to 45 
an alarming level requiring the development of new antibiotics. Although enzyme-46 
screening campaigns have dominated antibiotic discovery for years, their lack of 47 
success has prompted a change of strategy. In many instances, target identification of 48 
phenotypic hits is initiated by generating spontaneous drug-resistant mutants, with the 49 
expectation that resistance-conferring mutations will be revealed by whole genome 50 
sequencing (WGS)2-5. For instance, Bedaquiline was identified as an inhibitor of the 51 
M. tuberculosis F0F1 ATP synthase through WGS of spontaneous resistant mutants6. 52 
Using the same approach, MmpL3 was shown to be targeted by several inhibitors 53 
including SQ109, adamantyl ureas, BM212, THPPs, SPIROs and NITDs7-13. 54 
However, spontaneous resistance can occur through mutations not only in the drug 55 
target but also in other proteins linked to interactions between the cell and 56 
inhibitor14,15. In this study, we were able to exploit stereoselectivity of ligand binding 57 
in a quantitative affinity pull-down to identify the target of THPPs and reveal a novel 58 
fatty acid shuttle in mycobacteria.  59 
 60 
Results  61 
 62 
Target identification 63 
 64 
THPPs were prepared in a four-step synthetic route (Fig. 1a) and the desired 65 
enantiomer separated by chiral-HPLC. GSK366A and GSK951A12, and two novel 66 
THPP analogues, GSK059A and GSK572A, were included as tool compounds for 67 
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mode of action and structural studies. All compounds were endowed with selective 68 
anti-tubercular potency and were devoid of any significant cytotoxicity against 69 
HepG2 cell lines (Fig. 1b). Compound GSK951A was progressed to a dose response 70 
analysis in a murine model of chronic TB infection (Fig. 1c)12. Thus, GSK951A 71 
combines potency in culture with in vivo activity and lack of cytotoxicity. 72 
 73 
We applied a chemical proteomics strategy to identify the protein target(s) of the 74 
THPP lead compound directly in M. bovis BCG extracts. To this end, we synthesized 75 
carboxylic acid analogues of the active (GSK729) and inactive (GSK730) THPP 76 
enantiomers suitable for immobilization to Sepharose beads (Fig. 2). Each type of 77 
bead was incubated with M. bovis BCG extracts under three different conditions: (i) 78 
in presence of vehicle, (ii) in presence of excess “free” active enantiomer analogue, 79 
and (iii) in presence of excess “free” inactive enantiomer analogue. The relative 80 
protein content captured by the beads from each sample was quantified by isobaric 81 
tagging of tryptic peptides and tandem mass spectrometry analysis of the combined 82 
peptide pools in a 6-plex format16. Target proteins would be expected to bind 83 
selectively to beads derivatized with the active enantiomer analogue, a preference we 84 
probed by competition with free active vs free inactive enantiomers. Relative 85 
quantification (Supplementary Table 1 and 2) demonstrated that only a single 86 
protein showed a pronounced preference in this competition assay. The putative 87 
enoyl-CoA hydratase EchA6 showed robust inhibition (92%) by the active 88 
enantiomer GSK729 to the binding of GSK729-derived beads, but only insignificant 89 
inhibition (16%) by its inactive enantiomer GSK730 (Fig. 2a,b). MmpL3 was readily 90 
detected within the whole proteome analysis of the M. bovis BCG extract, but it was 91 
not identified in pull-downs with the immobilized THPP analogues.  This does not 92 
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necessarily rule it out as a target, since it could be due to either steric hindrance by the 93 
linker on the compound, low affinity, or denaturation of the extracted MmpL3. 94 
Supporting the specificity of the GSK729-beads, in similar experiments performed 95 
with HepG2 cells, the beads did not capture the closest human EchA6 orthologue, 96 
ECH1. To determine the affinity of GSK729 for EchA6 in M. bovis BCG extracts, we 97 
optimized the concentration of immobilized ligands on the beads, enabling a dose-98 
dependent binding of EchA6 to GSK729 in M. bovis BCG extracts with an IC50 of 1.8 99 
µM (Fig. 2c and Supplementary Table 2 and 3). 100 
 101 
EchA6 is essential and GSK951A inhibits mycolic acid biosynthesis 102 
 103 
To confirm essentiality we used a genetic tool termed CESTET17,18. Initially, a 104 
merodiploid strain in M. bovis BCG was generated that contained a second integrated 105 
copy of echA6 (Rv0905) under the control of the inducible tetracycline (ATc) 106 
promoter and subsequently the genomic copy was disrupted. As shown in 107 
Supplementary Figure 1a, the strain grew normally in liquid medium with ATc, but 108 
eventually showed cell lysis when grown in medium lacking ATc (Supplementary 109 
Fig. 1a, inset). To evaluate the effect of depletion of echA6 on both mycolic acid and 110 
fatty acid synthesis in M. bovis BCG, mycolic acid methyl esters (MAMES) and fatty 111 
acid methyl esters (FAMES) were prepared from cultures following labeling with 112 
[14C]-acetate. As shown in Supplementary Figure 1b, conditional depletion of 113 
echA6 results in a reduction of α-MAMES and keto-MAMES, while the overall 114 
abundance of FAMES remains largely unaffected, a classic hallmark of inhibitors 115 
targeting mycolic acid biosynthesis14,19. 116 
 117 
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In light of these findings we decided to further investigate our previous studies on the 118 
effects of THPPs on mycolic acid synthesis12. As shown in Figure 3a left panel, 119 
GSK951A suppresses the synthesis of all classes of MAMES in M. bovis BCG, while 120 
the overall abundance of FAMES remains largely unaffected. This result is similar to 121 
the mode of action of the thiolactomycin (TLM) and INH, well-known inhibitors of 122 
mycolic acid biosynthesis14,19 (Fig. 3a, right panel), supporting our earlier echA6 123 
conditional depletion experiments (Supplementary Fig. 1b). Further resolution of the 124 
FAMES by reverse-phase TLC indicated the accumulation of C26 FAMES (Fig. 3b), 125 
suggesting that THPPs act downstream of fatty acid synthase-I (FAS-I), and similar to 126 
the mode of action of INH (Fig. 3a,f). In addition, GSK951A significantly suppressed 127 
the synthesis of cell wall bound MAMES (Fig. 3a, middle panel). In marked 128 
contrast, using the inactive enantiomer, GSK540A, even at a minimum inhibitor 129 
concentration (MIC) of 20 × that of GSK951A, failed to inhibit total 130 
MAMES/FAMES and cell wall bound MAMES (Supplementary Fig. 2). Whole-cell 131 
target engagement of GSK951A was supported by increased resistance when echA6 132 
was overexpressed in M. bovis BCG. M. tuberculosis echA6 (Rv0905) was cloned into 133 
the multi-copy plasmid pVV16, which resulted in overexpression of His-tagged 134 
EchA6 as shown by Western Blot analysis (Fig. 3c).  Upon labeling cultures with 135 
[14C]-acetate, pVV16-echA6 containing strains revealed an elevated synthesis of 136 
MAMES (Supplementary Fig. 1c left panel, and d) and a 6-fold increased-resistance 137 
to GSK951A with solid or liquid media (MIC of 1.60 - 2.00 µM), in comparison to 138 
the pVV16 vector control strain (MIC of 0.32 µM) (Supplementary Fig. 1e and Fig. 139 
3d). Finally, the synthesis of cell wall bound MAMES in the pVV16-echA6 strain was 140 
less refractory to the addition of GSK951A at 1 × MIC compared to the pVV16 vector 141 
control strain (Supplementary Fig. 1c, right panel).  142 
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 143 
The addition of GSK951A to cultures up to 4 × the MIC resulted in no significant 144 
difference in terms of extractable cell envelope lipids (Supplementary Fig. 3, Panels 145 
A-C). The organic solvent extractable mycolates were markedly altered in the 146 
presence of GSK951A, and overall resulted in an elevated level of TMM 147 
(Supplementary Fig. 3, Panels D1 and D2). Indeed, confirmed MmpL3 inhibitors, 148 
including SQ109 and BM212, have been reported to cause significant accumulation 149 
of TMM13. Nevertheless, when applied at concentrations of up to 4 × their respective 150 
MICs, SQ109 or BM212 had no effect on total MAMES, and only moderately 151 
inhibited cell wall bound MAMES (Supplementary Fig. 2). In contrast, GSK951A 152 
effectively suppressed both total and cell wall bound MAMES at concentrations well 153 
below the 4 × MIC margin, emphasising the distinctive phenotypic response of 154 
GSK951A. Interestingly, we have observed an increased sensitivity to GSK951A 155 
when MmpL3 (Rv0206c) was overexpressed in M. bovis BCG using the multi-copy 156 
plasmid pMV261-mmpL3, in comparison to the pMV261 vector control 157 
(Supplementary Fig. 1f). Increased sensitivity to GSK951A would be consistent 158 
with MmpL3 moonlighting as a THPP importer, in addition to its function as a TMM 159 
exporter. Taken together, these findings provide strong evidence for THPPs acting 160 
upstream of fatty acid synthase-II (FAS-II) (Fig. 3f), without excluding the possibility 161 
of a downstream activity via MmpL3. To further probe the possible interaction of 162 
EchA6 with components of FAS-II, we conducted a protein-protein interaction screen 163 
using the bacterial two-hybrid system-BACTH. Interestingly, we found preliminary 164 
evidence for EchA6 interacting with two specific components of FAS-II (Fig. 3e,f). 165 
These included the β-ketoacyl-ACP synthase KasA, and the enoyl-ACP reductase 166 
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InhA (Fig. 3e). No interactions were observed with other specific components of the 167 
core multi-enzyme FAS-II complex20. 168 
 169 
Acyl-CoA and THPP ligand binding  170 
 171 
Initial inspection of the sequence of EchA6 and related family members from M. 172 
tuberculosis indicated that the conserved carboxylate side chains21 were mutated in 173 
EchA6, suggesting that EchA6, despite resembling an enoyl-CoA hydratase in overall 174 
sequence, was inactive. Nevertheless, residues involved in binding CoA are partially 175 
conserved in EchA6, leaving open the possibility that binding of acyl-CoAs was 176 
preserved, possibly as a mechanism for providing long-chain acyl-CoAs for fatty acid 177 
biosynthesis via FAS-II. Using intrinsic tryptophan fluorescence (ITF), we assayed 178 
variable chain-length acyl-CoA binding, which indicated that EchA6 has a clear 179 
preference for acyl-CoAs of chain-lengths 12 carbons or greater (Supplementary 180 
Table 4 and Fig. 4a). Ligand binding assays using EchA6 and THPPs were conducted 181 
to establish Kd values for a selection of compounds (Supplementary Table 4), 182 
highlighting that GSK951A (Fig. 4b) and GSK572A bound with the highest affinity 183 
as reflected by Kd values of 0.45 µM and 1.9 µM, respectively. In contrast, 184 
GSK573A, which is the inactive enantiomer of GSK572A, bound with a Kd of 285.8 185 
µM, a 150-fold increase, underscoring the distinct stereospecificity of the interaction 186 
between THPP compounds and EchA6 (Supplementary Table 4). Assessing C20-187 
CoA binding following pre-incubation of EchA6 with GSK951A, at concentrations of 188 
0.25 µM, 2.5 µM, and 10 µM of the drug, resulted in a distinct weakening of the 189 
interaction with C20-CoA, thus indicating competition for the same binding site (Fig. 190 
4c). Similar experiments with C4-CoA (Fig. 4d) indicated that competition between 191 
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acyl-CoA and GSK951A for the EchA6 binding site was not solely dependent on the 192 
acyl-chain. While C4-CoA bound with less affinity than C20-CoA, the Kd increased by 193 
similar margins when competing with GSK951A (Supplementary Table 4). 194 
However, the increase was monotonic for C4-CoA, while raising GSK951A above 2.5 195 
µM did not result in a further increase of Kd for binding of C20-CoA. Finally, 196 
introducing the point mutation, W133A, which maps to the THPP binding site (see 197 
Fig. 6), completely abolished THPP binding (Fig. 4b), whilst C20-CoA binding was 198 
weakened, but not abrogated (Supplementary Table 4). 199 
 200 
In vivo target engagement of THPPs and EchA6 201 
 202 
In an acute TB infection model22, M. tuberculosis transformed with a multi-copy 203 
plasmid-borne echA6W133A resulted in a significant shift in the in vivo effective dose 204 
99 (ED99) of GSK951A when compared to strains transformed with empty vector or 205 
vector containing echA6. (Fig. 1d). The echA6W133A strain resulted in a significant 206 
increase in the ED99 of GSK951A, from 85 and 77 mg/kg for the empty vector and 207 
echA6 strains, to >250 mg/kg for the echA6W133A strain (Fig. 1d, right panel). This 208 
increase of ED99 was well outside the calculated 95 % confidence interval (CI) for the 209 
empty vector and echA6 strains (41-182 mg/kg). As a control, all strains possessed 210 
similar ED99 values for INH (Fig. 1d, left panel) and were within the calculated 95 % 211 
CI range (0.2-3 mg/kg). While the empty vector and echA6 strains were able to grow 212 
at the same rate when inoculated into C57BL/6 mice in the acute TB infection model, 213 
the echA6W133A strain was relatively attenuated for growth (Fig. 1e), suggesting that 214 
the viability of M. tuberculosis in vivo was compromised by the EchA6 point 215 
mutation that weakened acyl-CoA binding. In addition, M. bovis BCG transformed 216 
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with a multi-copy plasmid-borne echA6W133A and grown in broth, showed a further 217 
increased resistance to GSK951A, possessing a MIC of 3.20 µM. This is in 218 
comparison to a M. bovis BCG strain transformed with plasmid-borne echA6 219 
possessing a MIC of 1.60 µM. Complete abrogation of THPP binding by EchA6W133A 220 
would suggest a more pronounced effect, however, the wild-type copy present in the 221 
overexpressing strain could account for the modest MIC and ED99 increase. 222 
 223 
X-ray crystallographic analysis of EchA6	  224 
 225 
X-ray crystallographic structures of EchA6 in the ligand-free form, bound to C20-CoA 226 
and several THPPs were determined by molecular replacement (Supplementary 227 
Table 5). EchA6 (Fig. 5a) consistently crystallized as a trimer (Fig. 5b), structurally 228 
resembling a flat disk with 3 extended substrate-binding grooves (Fig. 5c). The 229 
binding sites of the CoA-moiety and the THPPs reside on the ‘front’ and ‘back’ faces 230 
of the trimer, respectively (Fig. 5c).  231 
 232 
The EchA6 monomer is structurally similar to the rat liver enoyl-CoA hydratase 233 
(RnECH)23 (Fig. 5a,b and Supplementary Fig. 4a). However, the C-terminal helices 234 
α10 and α11 diverge from the orientation seen in RnECH (Supplementary Fig. 4a). 235 
In RnECH, the backbone turns 180º after helix α9 and helix α10 runs anti-parallel to 236 
α9, whereas in EchA6, helices α10 and α11 project forward and fold back onto the 237 
monomer (Fig. 5a). Despite the altered backbone conformation, helices α10 and α11 238 
still occupy analogous interfacial positions between the monomers in the context of 239 
the trimer (Fig. 5b).  240 
 241 
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Enoyl-CoA hydratases belong to the crotonase superfamily of enzymes, which display 242 
diverse structural scaffolds and catalyze a wide variety of reactions, involving CoA-243 
linked substrates24. Among structural neighbours identified by distance matrix 244 
alignment (DALI)25, EchA6 aligns most closely with crotonases mediating enoyl-245 
CoA hydratase activity (e.g. RnECH, Supplementary Fig. 4a), in line with its 246 
annotation in sequence databases. Yet, the catalytic residues are not conserved in 247 
EchA6. The hydratase reaction converts the C2-C3 double bond of enoyl-CoA into a 248 
single bond and adds a hydroxyl to C3. Polarization is facilitated by positioning the 249 
acyl-keto oxygen against the amide nitrogens of nearby glycine and alanine residues 250 
(Gly141, Ala98 in RnECH), while two carboxylate side chains (Glu144, Glu164 in 251 
RnECH) coordinate the attacking water21,23 (Fig. 5d). Comparing the structures of 252 
EchA6 and RnECH (30.8% sequence identity), the oxyanion hole backbone amides 253 
are conserved (Ala100, Ala60), but the carboxylate side chains are substituted by 254 
glutamine (Gln103 for Glu144 of RnECH) and threonine (Thr123 for Glu164 of 255 
RnECH), respectively (Fig. 5d). In contrast, the structural alignment of RnECH with 256 
M. tuberculosis EchA8 (PDB entry 3PZK, 50.2 % identity) demonstrates complete 257 
conservation of key residues in the active site (Supplementary Fig. 4b). 258 
Nevertheless, the C20-CoA bound complex of EchA6 (Supplementary Fig. 4c) 259 
demonstrates a conserved mode of CoA-binding, with the thioester superimposing 260 
closely with the thioesters in the acetoacetyl-CoA bound complexes of RnECH (PDB 261 
entry 1EY3,21) and EchA8 (PDB entry 3Q0J). In addition, binding C20-CoA to EchA6 262 
induces a conformational change in the β3-α3 loop (residues 61-68), transforming the 263 
substrate-binding groove into a tunnel between the ‘front’ and the ‘back’ face of the 264 
EchA6 trimer (green subunit in Fig. 5c).   265 
 266 
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In order to define the structural determinants of THPP inhibition, we solved structures 267 
of EchA6 in complex with five different THPPs (Supplementary Table 5, Fig. 6a, 268 
and Supplementary Fig. 4d-h), including the lead compound GSK951A (Fig. 1a). In 269 
the trimeric molecule, all 3 subunits are occupied by the ligand. Superposition of 270 
ligand-bound and apo structures reveal only minor conformational adjustments of 271 
side chains contacting the ligand. Situated on the ‘back’ face of the EchA6 trimer 272 
(Fig. 5c), the inhibitor-binding site overlaps partially with the putative active site of 273 
EchA6 (marked by the conserved oxyanion hole of Ala100 and Ala60), but mostly 274 
occupies the extended hydrophobic groove, which accommodates the acyl-chain in 275 
the C20-CoA complex (Fig. 5c and Fig. 6b). The mode of binding is consistent 276 
between all THPP-complexed structures (Supplementary Table 5 and 277 
Supplementary Fig. 4d–h). A slightly different ligand conformation is observed for 278 
GSK366A (Supplementary Fig. 4f), but the difference could be the result of 279 
different crystal symmetries (Supplementary Table 5), due to packing-induced 280 
structural changes of the protein. The complex with the bait compound, GSK729A, 281 
matches the binding mode of the other complexes (Supplementary Fig. 4h). 282 
Interactions with EchA6 are dominated by hydrophobic and van der Waals (vdW) 283 
contacts. The pyrazolo-pyrimidine group is central to the interaction with the protein. 284 
The trifluoromethyl-substituent forms hydrogen bonds with His79 (to Nε2) and 285 
Gln103 (to Oε1 and Nε2), with an additional vdW contact to Ile76 (Cδ1) (Fig. 6c). 286 
The ethylphenyl group forms hydrophobic contacts with Trp133, the β-carbon of 287 
Asp83 and the δ-carbon of Gln107 (Fig. 6c). For GSK951A, the terminal benzodioxol 288 
group stacks on top of Phe216, with additional vdW contacts with the α-carbon of 289 
Lys213 and the β-carbon of Ala208.  290 
 291 
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Discussion 292 
 293 
Target identification by stereoselective quantitative pull-downs points to EchA6 as 294 
the target of THPPs and is supported by a string of orthogonal evidence. This is in 295 
contrast to the recent target assignment of THPPs as MmpL312, exposing an inherent 296 
weakness of target identification by WGS of THPP-resistant mutants. Resistance-297 
conferring mutations against THPPs have not yet been observed in echA6, however, 298 
our targeted mutagenesis studies have induced resistance, which strongly supports 299 
THPPs acting through EchA6. The absence of SNPs in echA6 in spontaneous resistant 300 
mutants is not unexpected, since INH-resistance is caused by mutations in inhA in 301 
only 2% of clinical isolates26.  302 
 303 
We demonstrate that THPPs potently suppress mycolic acid biosynthesis (Fig. 3 and 304 
Supplementary Fig. 1). This phenotypic effect is distinct from other WGS-confirmed 305 
MmpL3 inhibitors, such as SQ10913 and BM2128 (Supplementary Fig. 2). Previous 306 
studies have used high concentrations of MmpL3 inhibitors (ranging from 3 × to 10 × 307 
MIC) and it is conceivable that the significant accumulation of TMM may be a result 308 
of a stress response. However, the frequency of the MmpL3 resistance phenotype and 309 
the increased sensitivity to THPPs upon overexpression of mmpL3 gives credence to 310 
the possibility of MmpL3 moonlighting as a drug importer.  311 
 312 
Importantly, we demonstrate that echA6 is essential in mycobacteria and is conserved 313 
across several mycobacterial genomes (Supplementary Table 6), including the 314 
‘essential’ minimal M. leprae genome27. Although the exact function of EchA6 315 
remains to be established, we show that EchA6 has a distinct preference for long-316 
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chain acyl-CoAs and interacts with selective components of FAS-II. We postulate that 317 
EchA6 acts as a shuttle for fatty acid transfer, bypassing the non-essential FabH28. 318 
Overall, this would be compatible with its catalytically silent state, potential partners 319 
identified by STRING analysis (Supplementary Fig. 5)29 and its unique extended 320 
acyl-CoA binding groove relative to the other 20 mycobacterial EchAs. The diversity 321 
of crotonase family members in terms of enzymatic activity and substrates (albeit all 322 
CoA-linked) leaves the door open to an alternative, as yet unidentified catalytic 323 
activity. Emerging from these considerations is a model (Fig. 3f) that places EchA6 at 324 
a critical junction between FAS-I, β-oxidation and FAS-II pathways. 325 
 326 
In conclusion, we have shown that THPPs mediate bactericidal activity in a mouse 327 
infection model of tuberculosis and that these compounds act on the catalytically 328 
silent enoyl-CoA hydratase-like EchA6 protein. This surprising result of our 329 
alternative target deconvolution approach suggests that spontaneous resistance-330 
conferring mutations can potentially obscure the actual target or alternative targets of 331 
inhibitors emerging from phenotypic screening campaigns. 332 
 333 
334 
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Supplementary information is linked to the online version of the paper. 334 
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Figures Legends 357 
 358 
Figure 1. THPP chemical structures and in vivo anti-tubercular activity. (a) 359 
Synthesis of THPPs. (b) M. tuberculosis H37Rv, M. bovis BCG, anti-bacterial and 360 
cytotoxicity profile of THPPs. The human biological samples were sourced ethically 361 
and their research use was in accordance with the terms of informed consent. (c) 362 
Efficacy of GSK951A against an established murine model of M. tuberculosis chronic 363 
infection. Mean ± SD is shown for each treated mice group (n = 3-7 mice/group). (d) 364 
The ED99 of GSK951A and INH in a murine model of M. tuberculosis acute 365 
infection22 using M. tuberculosis transformed with either a multi-copy plasmid-borne 366 
empty vector control, echA6 or echA6W133A. LogCFU counts are shown as the 367 
difference with respect to the untreated control group infected with each strain 368 
(∆logCFU/mouse). (e) The relative growth of each strain used in panel d. For both 369 
panels (d,e), each data point represents an individual mouse. All animal studies were 370 
ethically reviewed and carried out in accordance with European Directive 210/63/EU 371 
and the GSK Policy on the Care, Welfare and Treatment of Animals. 372 
 373 
Figure 2: Chemoproteomics profiling identifies the putative enoyl-CoA 374 
hydratase EchA6 as target of the THPP series. (a) EchA6 is captured from M. 375 
bovis BCG extracts with beads derivatized with GSK729. (b) EchA6 binds to beads 376 
derivatized with the active enantiomer analogue GSK729 but not the inactive 377 
enantiomer analogue GSK730. Binding is only competed by the active enantiomer 378 
(Supplementary Table 1 and 2). (c) Estimation of the affinity of GSK729 for EchA6 379 
(Supplementary Table 3).  380 
 381 
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Figure 3. GSK951A inhibition of mycolic acid biosynthesis, resistance and 382 
protein-protein interaction studies. (a,b) [14C]-Acetate labeling and dose-response 383 
of GSK951A, INH and TLM against M. bovis BCG. Total MAMES and FAMES (a, 384 
left and right panels, n = 3 biological replicates), reverse-phase TLC (b, n = 2 385 
biological replicates) and cell wall bound MAMES (a, middle panel, n = 2 biological 386 
replicates) were isolated and equal counts for the former two, and an equal aliquot for 387 
the latter were analysed by TLC13,14,30. (c) SDS-PAGE (left panel) and Western blot 388 
(right panel) analysis of pVV16 and pVV16-echA6 cytosolic lysates (n = 3 biological 389 
replicates).  (d) Overexpression of M. tuberculosis EchA6 using pVV16-echA6 in M. 390 
bovis BCG (n = 5 biological replicates). (e) Protein-protein interaction screen using 391 
the bacterial two-hybrid system BACTH and EchA6 with components of FAS-II (n = 392 
3 biological replicates). (f) Proposed biosynthetic model linking FAS-I, FAS-II and 393 
the β-oxidation pathways, providing a key role for EchA6 as a conduit for supplying 394 
acyl-CoA primers for mycolic acid biosynthesis. 395 
 396 
Figure 4. Saturation binding assay using intrinsic tryptophan fluorescence to 397 
quantify association of EchA6 with acyl-CoAs and THPPs. (a) Saturation binding 398 
curves for C4-CoA, C12-CoA, and C20-CoA. (b) Comparison of saturation binding of 399 
GSK951A between EchA6 and EchA6W133A. (c,d) Competition binding assay of C20-400 
CoA and C4-CoA in the presence of 0−10 µM GSK951A. Kd values (mean ± SD) 401 
resulting from non-linear least squares fitting of a single-site binding model are listed 402 
in Supplementary Table 4. Data were fitted using GraphPad Prism.  403 
 404 
Figure 5. Structural features of EchA6 in the free and C20-CoA bound state. (a) 405 
Ribbon diagram of the EchA6 monomer, bound to C20-CoA (yellow sticks). 406 
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Secondary structure elements are labeled analogous to the structure of RnECH23. (b) 407 
Ribbon diagram of the EchA6 trimer superimposed with the structure of R. 408 
norvegicus enoyl-CoA hydratase (RnECH). EchA6 subunits are beige, green and 409 
blue, RnECH is cyan. (c) Molecular surface of the ‘front’ and ‘back’ face of the 410 
EchA6 trimer bound to C20-CoA (subunit A in green). The binding sites of the 411 
inhibitor GSK951A are indicated for subunits B and C by the stick model in cyan. (d) 412 
Superposition of the active sites of RnECH (cyan) and EchA6 (yellow). Dashed lines 413 
indicate the H-bond interactions that mediate polarization of the keto-moiety of CoA 414 
in the hydratase reaction.  415 
 416 
Figure 6. Binding site of GSK951A in EchA6. (a) The molecular surface of EchA6 417 
is shown in translucent rendering and amino acid side chains within a 4 Å radius 418 
around the ligand are shown as sticks. The σA-weighted 2Fo-Fc density map is 419 
contoured at 1.0 σ and was calculated with coordinates of GSK951A included in the 420 
model. (b) Superposition of GSK951A (carbon atoms in cyan) and CoA-bound 421 
structure of EchA6. The thioester sulfur (green) of C20-CoA is indicated. (c) 422 
Schematic diagram of contacts between GSK951A and EchA6. Polar contacts are 423 
indicated with a dashed line, vdW and hydrophobic contacts with a hashed line. 424 
425 
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Methods 477 
 478 
General information for chemical synthesis 479 
 480 
Automated flash chromatography was performed on a Biotage FlashMaster II system 481 
with peak detection at 254 nm. 1H NMR spectra were recorded at 400 MHz on a 482 
Bruker Ultrashield DPX 400 spectrometer. Chemical shifts (δ) are given in ppm 483 
relative to the solvent reference as an internal standard (DMSO-d6, δ = 2.50 ppm; 484 
CDCl3, δ = 7.27 ppm). Data are reported as follows: chemical shift (multiplicity (s for 485 
singlet, d for doublet, t for triplet, q for quartet, m for multiplet, br for broad), 486 
integration, coupling constant(s) in Hz). HPLC–MS analyses were conducted on an 487 
Agilent 1100 instrument equipped with a Sunfire C18 column (30 × 2.1 mm i.d., 3.5 488 
mm packing diameter) at 40ºC coupled with a Waters ZMD2000 mass spectrometer; 489 
the method of ionization was alternate-scan positive and negative electrospray. Semi-490 
preparative chiral HPLC was conducted on an Agilent 1100 instrument equipped with 491 
a Chiralpak IC column (250 mm x 20 mm). Preparative chiral HPLC was conducted 492 
on a Varian SD-2 prep HPLC instrument equipped with a Chiralpak IC column (250 493 
mm x 50 mm i.d, 20 µm packing diameter). Compounds had a purity of >95 %, as 494 
determined by HPLC and 1H NMR analysis. 495 
 496 
Ethyl 7-(4-ethylphenyl)-7-methylpyrazolo[1,5-a]pyrimidine-3-carboxylate. A 497 
mixture of ethyl 3-aminopyrazole-4-carboxylate (2.99 g, 19.24 mmol), 1-(4-498 
ethylphenyl)-1,3-butanedione (3.66 g, 19.24 mmol) and acetic acid (15 ml) was 499 
heated at reflux for 6 h. LC-MS analysis showed an 80/20 mixture of two products. 500 
After cooling to room temperature, the reaction mixture was poured onto ice (60 g). 501 
   26 
The solid formed was filtered off, triturated with hexane and dried to afford a pale 502 
yellow solid. The crude product was added to a silica gel column (40 g) and eluted 503 
with a mixture of EtOAc/hexane (gradient 0-20 %). Collection of the appropriate 504 
fractions afforded the desired compound (747 mg, 2.42 mmol, 13 %) as a white solid 505 
along with a regioisomeric by-product (2.98 g, 9.63 mmol, 50 %). 1H NMR (400 506 
MHz, CDCl3+D2O) δ ppm: 8.58 (s, 1H), 8.15-8.17 (m, 2H), 7.35-7.37 (m, 2H), 7.33 507 
(s, 1H), 4.46 (q, 2H, J=7.1), 2.89 (s, 1H), 2.74 (q, 2H, J=7.6), 1.48 (t, 3H, J=7.1), 1.30 508 
(t, 3H, J=7.6). 509 
 510 
cis-Ethyl 5-(4-ethylphenyl)-7-methyl-4,5,6,7-tetrahydropyrazolo[1,5-511 
a]pyrimidine-3-carboxylate. To a solution of ethyl 5-(4-ethylphenyl)-7-512 
methylpyrazolo[1,5-a]pyrimidine-3-carboxylate (710 mg, 2.30 mmol) in anhydrous 513 
methanol (10 ml), 10 % Pd/C (244 mg, 0.23 mmol) was added. The reaction was 514 
hydrogenated at 40 psi for 24 h. LC-MS showed completion of the reaction. The 515 
mixture was filtered over celite and concentrated in vacuo affording the desired 516 
compound (714 mg, 2.23 mmol, 99 %) as a white solid. The product was used in the 517 
next step without further purification. 1H NMR (400 MHz, CDCl3+D2O) δ ppm: 7.66 518 
(s, 1H), 7.33-7.35 (m, 2H), 7.22-7.24 (m, 2H), 5.93 (bs, 1H), 4.56 (dd, 1H, J=11.6 and 519 
2.8), 4.28-4.36 (m, 1H), 4.24 (q, 2H, J=7.1), 2.68 (q, 2H, J=7.6), 2.29-2.35 (m, 1H), 520 
2.00 (dt, 1H, J=13.4 and 11.1), 1.61 (d, 3H, J=6.3), 1.32 (t, 3H, J=7.1), 1.26 (t, 3H, 521 
J=7.6). 522 
 523 
cis-5-(4-Ethylphenyl)-7-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-524 
carboxylic acid. To a solution of cis-ethyl 5-(4-ethylphenyl)-7-methyl-4,5,6,7-525 
tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxylate (700 mg, 2.23 mmol) in ethanol 526 
(5 ml), a 1.5 M KOH aqueous solution (5.21 ml, 7.82 mmol) was added and the 527 
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reaction was stirred at 60ºC for 12 h. The reaction was concentrated in vacuo to 528 
remove the organic solvent and a saturated citric acid solution was then added until 529 
acidic pH. The solid was collected by filtration, washed with water and dried to afford 530 
the desired compound (539 mg, 1.89 mmol, 85 %) as a white solid. 1H NMR (400 531 
MHz, DMSO-d6) δ ppm: 11.8 (bs, 1H), 7.49 (s, 1H), 7.33-7.35 (m, 2H), 7.22-7.24 (m, 532 
2H), 6.04 (bs, 1H), 4.58 (dd, 1H, J=11.1 and 2.3), 4.22-4.32 (m, 1H), 2.61 (q, 2H, 533 
J=7.6), 2.25-2.35 (m, 1H), 1.87 (dt, 1H, J=13.1 and 10.9), 1.43 (d, 3H, J=6.3), 1.18 (t, 534 
3H, J=7.6). [ES+ MS] m/z 286 (M+H)+. 535 
 536 
(5R,7R)-N-(4-fluorobenzyl)-5-(4-ethylphenyl)-7-methyl-4,5,6,7-537 
tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide (GSK059A). To a solution 538 
of cis-5-(4-ethylphenyl)-7-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-539 
carboxylic acid (100 mg, 0.35 mmol) in N,N-dimethylformamide (3 ml), HATU (160 540 
mg, 0.42 mmol) and N,N-Disopropylethylamine (0.306 ml, 1.75 mmol) were added. 541 
The mixture was stirred at room temperature for 30 min. (4-542 
fluorophenyl)methanamine hydrochloride (85 mg, 0.53 mmol) was added and the 543 
mixture was stirred at 60ºC for 3 days. LC-MS showed the desired product as major 544 
and no starting material. After cooling to room temperature, the reaction mixture was 545 
diluted with TBME and washed with saturated NH4Cl aqueous solution and brine. 546 
The organic layers were concentrated and the residue was added to a silica gel column 547 
(5 g) and eluted with a mixture of EtOAc/cyclohexane (gradient 0-60 %). Collection 548 
of the appropriate fractions afforded the desired racemic compound (116 mg, 0.296 549 
mmol, 84 %) as a white solid. The enantiomers were separated by semipreparative 550 
HPLC (flow: 18 ml/min; solvent: hexane/EtOH 90/10; column: Chiralpak IC, 250 551 
mm x 20 mm). The desired enantiomer eluted at 15 min and the opposite at 23 min. 552 
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The title compound was obtained (35 mg, 0.089 mmol) as a white solid 553 
enantiomerically pure by HPLC. 1H NMR (400 MHz, CDCl3) δ ppm: 7.50 (bs, 1H), 554 
7.27-7.34 (m, 4H), 7.20-7.22 (m, 2H), 6.99-7.04 (m, 2H), 6.47 (bs, 1H), 5.94 (bs, 1H), 555 
4.44-4.58 (m, 3H), 4.27-4.37 (m, 1H), 2.66 (q, 2H, J=7.6), 2.28-2.36 (m, 1H), 1.96-556 
2.08 (m, 2H), 1.61 (d, 3H, J=6.1), 1.25 (t, 3H, J=7.8). [ES+ MS] m/z 393 (M+H)+. 557 
 558 
(5-Fluoropyridin-2-yl)methanamine dihydrochloride. A mixture of 5-559 
fluoropicolinonitrile (300 mg, 2.457 mmol), 10 % wt. palladium on carbon (60 mg, 560 
0.056 mmol), methanol (25 ml) and concentrated HCl (1 ml, 11.70 mmol) was stirred 561 
at room temperature under 30 psi of hydrogen. After 4 h the reaction was filtered 562 
through celite washing with 200 ml of methanol. Evaporation afforded the desired 563 
compound (500 mg, 2.39 mmol, 97%) as an off-white solid. 1H NMR (400 MHz, 564 
DMSO-d6) δ ppm: 8.32-9.32 (m, 4H), 8.63 (d, 1H, J=2.8), 7.84 (td, 1H, J=8.8 and 565 
3.0), 7.64 (dd, 1H, J=8.6 and 4.3), 4.17 (bq, 2H, J=5.8). 566 
 567 
(5R,7S)-5-(4-ethylphenyl)-N-((5-fluoropyridin-2-yl)methyl)-7-(trifluoromethyl)-568 
4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide (GSK572A). To a 569 
solution of cis-5-(4-ethylphenyl)-7-(trifluoromethyl)-4,5,6,7-tetrahydropyrazolo[1,5-570 
a]pyrimidine-3-carboxylic acid (200 mg, 0.589 mmol) in N,N-dimethylformamide (5 571 
ml) at room temperature under nitrogen, HATU (269 mg, 0.707 mmol) was added 572 
followed by N,N-diisopropylethylamine (0.309 ml, 1.768 mmol). The mixture was 573 
stirred at room temperature for 15 min and then a solution of (5-fluoropyridin-2-574 
yl)methanamine dihydrochloride (153 mg, 0.766 mmol) and N,N-575 
diisopropylethylamine (0.309 ml, 1.768 mmol) in N,N-dimethylformamide (3 ml) was 576 
added. The mixture was stirred at room temperature for 3 days. The reaction mixture 577 
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was diluted with EtOAc (30 ml) and washed with saturated aqueous NaHCO3 (3 x 40 578 
ml), water (40 ml) and 1M NH4Cl (3 x 40 ml). The organic layer was dried, filtered 579 
and evaporated. The residue was added to a silica gel column and eluted with a 580 
mixture of EtOAc/cyclohexane (gradient 0-100 %). Collection of the appropriate 581 
fractions afforded the desired racemic compound (221 mg, 0.469 mmol, 80 %) as an 582 
off-white solid. The enantiomers were separated by semipreparative HPLC (flow: 18 583 
ml/min; solvent: hexane/EtOH 90/10; column: Chiralpak IC, 250 mm x 20 mm). The 584 
desired enantiomer (GSK572A) eluted at 15 min and the opposite (GSK573A) at 23 585 
min. The title compound was obtained (93 mg, 0.197 mmol) as a white solid 586 
enantiomerically pure by HPLC. 1H NMR (400 MHz, CDCl3) δ ppm: 8.42 (d, 1H, 587 
J=2.8), 7.63 (s, 1H), 7.31-7.42 (m, 4H), 7.22-7.24 (m, 2H), 6.60-6.64 (m, 2H), 4.81-588 
4.89 (m, 1H), 4.66 (dd, 1H, J=16.7 and 5.3), 4.62 (dd, 1H, J=16.7 and 5.3), 4.54 (dd, 589 
1H, J=11.6 and 2.5), 2.67 (q, 2H, J=7.6), 2.50-2.56 (m, 1H), 2.33-2.42 (m, 1H), 1.25 590 
(t, 3H, J=7.8). [ES+ MS] m/z 448 (M+H)+. 591 
 592 
General methods 593 
 594 
The measurement of the MIC for each tested compound, general antimicrobial 595 
activity, microsomal fraction stability, pharmacokinteic studies, HepG2 cytotoxicity 596 
assay, SDS-PAGE and Western blot were performed as described previously2,19,30. 597 
EchA6 (Rv0905) was cloned into the mycobacterial multi-copy plasmid pMV261 and 598 
its derivatives30; the site-directed mutant EchA6W133A was generated using the 599 
plasmids containing wild-type echA6 and QuikChange II (Agilent Technologies). 600 
MmpL3 (Rv0206c) was cloned into pMV261. The constructs were electroporated into 601 
either M. bovis BCG or M. tuberculosis. The primers are described in Supplementary 602 
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Table 7. The in vitro effect of GSK951A, TLM, and INH was studied by treating M. 603 
bovis BCG cultures at OD600 of 0.4 with inhibitor for 24 hours, followed by [14C]-604 
acetate labeling for 24 hours, and subsequent analysis of either total FAMES and 605 
MAMES (equal counts, typically 30,000 cpm), cell wall bound MAMES (equal 606 
volumes, 5 % aliquot), or cell envelope lipids (equal counts, typically 30,000 cpm) as 607 
described previously13,14,19,30-32. Protein-protein interactions were studied using the 608 
bacterial adenylate cyclase based two-hybrid system as described33. Briefly, echA6 609 
(Rv0905) was cloned using the primers described in Supplementary Table 7 into 610 
pUT18 in-frame with the T18 fragment, and the FAS-II genes cloned into pKT25 in-611 
frame with the T25 fragment. The positive control pKT25 was fused to the Leucine 612 
Zipper of GCN4 co-transformed with pUT18C of the Leucine Zipper GCN4. The 613 
negative control was pKT25 Zip co-transformed with empty pUT18 vector. The GSK 614 
in-house hydrophobicity assay was performed using 10 µl of a 10 mM DMSO stock 615 
solution diluted to 750 µl with octanol saturated phosphate buffer pH 7.4 and 160 µl 616 
buffer saturated octanol in a 96-well deep well block. Blocks were sealed and inverted 617 
for 3 sets of 50 inversions, then centrifuged at 300 g for 20 min. Both phases were 618 
quantified using generic gradient UV-HPLC.  619 
 620 
Assessment of chronic and acute efficacy in murine TB models 621 
 622 
The assessment of the chronic and acute efficacy in murine TB models was performed 623 
using specific pathogen-free, 8-10 week-old female C57BL/6 mice purchased from 624 
Harlan Laboratories and allowed to acclimate for one week. In the chronic model, 625 
mice (n = 3-7 mice per dose level, a total of 27/28 mice per compound) were 626 
intratracheally infected with 100 CFU/mouse and GSK951A formulated in 1 % 627 
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aqueous methylcellulose and administered daily for 8 consecutive weeks, starting 6 628 
weeks after infection. Lungs were harvested 24 h after the last administration. All 629 
lung lobes were aseptically removed, homogenized and frozen. Homogenates were 630 
plated on 10 % OADC-7H11 medium supplemented with activated charcoal (0.4 %) 631 
for 18 days at 37ºC. In the acute model22, mice were intratracheally infected with 632 
50,000 CFU/mouse with all strains, and lungs harvested on day 9. GSK951A and INH 633 
(in water) were administered daily for 8 consecutive days, starting on day 1 after 634 
infection. All lung lobes were aseptically removed, homogenized, and plated in 10 % 635 
OADC-7H11 medium supplemented with activated charcoal (0.4 %) and grown for 636 
18-25 days at 37ºC. Lung logCFUs vs dose was fitted to a logistic equation (sigmoidal 637 
dose response, variable slope, GraphPad Prism software). Effective dose 99 % (ED99), 638 
defined as the dose in mg/kg that reduced lung bacterial burden at day 9 after 639 
infection by 99 % (2 logCFU) with respect to untreated, was calculated by 640 
interpolation in the sigmoidal curve. The number of mice was selected as the 641 
minimum number of mice that is necessary to detect a 3-fold difference in the ED99 of 642 
two different products.  Mice were randomly allocated to the different experimental 643 
groups immediately after the infection. 644 
 645 
Preparation of M. bovis BCG cytosolic extract 646 
 647 
M. bovis BCG cell pellets were resuspended in lysis buffer (50 mM Tris-HCl, pH 7.4, 648 
1 mM EDTA, 7.5 % glycerol, 150 mM NaCl, 25 mM NaF, 1 mM Na3VO4, 1 mM 649 
DTT, and 1 complete EDTA-free protease inhibitor tablet (Roche) per 25 ml). After 650 
sonication the samples were adjusted to 0.8 % Igepal-CA630 and extraction was 651 
completed by homogenization using a Dounce homogenizer. After 45 min rotation at 652 
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4ºC, the samples were subjected to centrifugation for 10 min at 20,000 g at 4ºC. The 653 
supernatant was kept on ice, while the pellet was re-extracted with 1 volume of lysis 654 
buffer adjusted to 0.8 % Igepal-CA630. The pellet was resuspended using a long 20 655 
gauge needle (2x), followed by rotation for 30 min at 4ºC. After a centrifugation step 656 
as described above, both supernatants were pooled and subjected to centrifugation at 657 
100,000 g for 1 h at 4ºC. The final supernatant was snap frozen in liquid nitrogen and 658 
stored at -80ºC. 659 
 660 
Chemoproteomics 661 
 662 
Sepharose beads were derivatized with GSK729A at various concentrations from 0.05 663 
mM to 2 mM. Beads (35 µl) were washed and equilibrated in lysis buffer incubated at 664 
4ºC for 1 h with 1 ml (1 mg) M. bovis BCG cytosolic extract, which was pre-665 
incubated with compound or buffer. Beads were transferred to disposable columns 666 
(MoBiTec), washed extensively with lysis buffer and eluted with SDS sample buffer. 667 
Proteins were alkylated, separated on 4-12 % NuPAGE (Invitrogen), stained with 668 
colloidal Coomassie, and quantified by isobaric tagging and LC-MS/MS. Digestion, 669 
labeling with TMT isobaric mass tags, peptide fractionation, and mass spectrometric 670 
analyses were performed essentially as described16. The proteins.fasta file for M. 671 
bovis BCG was downloaded (May 11th 2011) from 672 
http://genome.tbdb.org/annotation/genome/tbdb/MultiDownloads.html and 673 
supplemented with the sequences of bovine serum albumin, porcine trypsin and 674 
mouse, rat, sheep and dog keratins. Decoy versions of all proteins were created and 675 
added. The search database contained a total of 11,492 protein sequences, 50 % 676 
forward, 50 % reverse. Criteria for protein quantification were: a minimum of 2 677 
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sequence assignments matching to unique peptides (FDR for quantified proteins 678 
<<0.1 %), Mascot ion score > 15, signal to background ratio of the precursor ion > 4, 679 
signal to interference > 0.534. Reporter ion intensities were multiplied with the ion 680 
accumulation time yielding an area value proportional to the number of reporter ions 681 
present in the mass analyzer. Peptide fold changes were corrected for isotope purity as 682 
described and adjusted for interference caused by co-eluting nearly isobaric peaks as 683 
estimated by the signal-to-interference measure35. Protein quantification was achieved 684 
using a sum-based bootstrap algorithm36. 685 
 686 
Generation and characterisation of a conditional echA6 mutant in M. bovis BCG 687 
 688 
A conditional mutant in the M. bovis BCG homologue of M. tuberculosis echA6 was 689 
generated using the genetic tool CESTET17,18. First, a recombinant echA6 knockout 690 
phage was designed to replace the M. bovis BCG echA6 homologue. The primers used 691 
for amplifying the left and right flanks to generate the allelic exchange substrate17,18 692 
are provided in Supplementary Table 7. Next, Rv0905 was PCR amplified using the 693 
primers mdRv0905_F and mdRv0905_R (Supplementary Table 7) and cloned 694 
downstream of the tetracycline promoter into the integrating vector pTIC6a to 695 
generate the plasmid pTIC6a-Rv090517,18. A merodiploid strain was then constructed 696 
by electroporating pTIC6a-Rv0905 into M. bovis BCG. The resultant strain 697 
BCG::Rv0905 was then transduced with echA6 knockout phage. Transductants were 698 
selected on 7H10-agar plates containing 25 µg/ml kanamycin, 75 µg/ml hygromycin 699 
and 50 ng/ml anhydrotetracycline (ATc). One confirmed knockout strain was called 700 
∆BCG0957 and was used in a conditional depletion experiment to detect cell death as 701 
shown previously in minimal medium17,18.  702 
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 703 
Recombinant production and purification of EchA6 and EchA6W133A 704 
 705 
The gene echA6 (Rv0905) was amplified by PCR (Supplementary Table 7) and 706 
cloned into plasmid pET28a (Novagen). Briefly, E. coli BL21 (DE3) transformed 707 
with pET28a-echA6 or pET28a-echA6W133A (through site-directed mutagenesis of 708 
pET28a-echA6; the primers are described in Supplementary Table 7) were grown in 709 
Luria Bertani (LB) broth from a glycerol stock (37ºC, 180 rpm, shaking), grown 710 
overnight and used to inoculate flasks containing 1 L of LB media containing 50 711 
µg/ml kanamycin. Bulk cultures were grown (37ºC, 180 rpm) shaking to OD600 = 0.4-712 
0.6, and induced with 1 mM IPTG, reducing the incubation temperature to 16ºC. 713 
Batch culture was continued at 16ºC until 24 h post-induction at which point cultures 714 
were harvested by centrifugation at 5,000 rpm at 4ºC and the pellets stored at –20ºC. 715 
Cell pellets were defrosted and resuspended in 20 ml of lysis buffer (50 mM sodium 716 
phosphate, 600 mM sodium chloride and 10 mM imidazole, pH 8) with a complete 717 
EDTA-free Protease Inhibitor Cocktail Tablet (Roche), and sonicated on ice with 10 718 
cycles of 30 sec sonication and 30 sec cooling, and centrifuged (40 min, 15,000 rpm, 719 
4ºC). For purification of the His6-tagged EchA6 (and EchA6W133A) protein, a His-trap 720 
HP column (GE Healthcare Life Sciences) was used following the manufacturers 721 
guidelines using a step-wise gradient of 50 mM, 125 mM, 150 mM and 200 mM 722 
imidazole in buffer. Eluates were analyzed by 12 % SDS-PAGE (Bio-Rad) run at 200 723 
V, 50 mA for 40 min. Gels were stained with Instant Blue (Expedeon). Fractions 724 
containing pure protein were dialyzed overnight in 2 L of dialysis buffer (25 mM 725 
HEPES, 10 % glycerol and 300 mM NaCl, pH 8). EchA6 was then concentrated by 726 
   35 
centrifugation to >30 mg/ml using a spin column (Thermo Scientific) and the 727 
concentration of protein was determined by absorption spectroscopy at 280 nm. 728 
 729 
X-ray crystallographic structure determination 730 
 731 
Crystals of EchA6 in the ligand-free form and bound to THPP compounds or C20-732 
CoA were obtained by vapour diffusion at 18ºC, using commercial sparse matrix 733 
screens JCSG-plus and MIDAS (Molecular Dimensions) in 96-well sitting drop plates 734 
(SWISSCI 3-lens). A liquid handling robot (Mosquito) was used to dispense 300 nl 735 
drops consisting of 150 nl protein at concentrations between 20 and 30 mg/ml plus 736 
150 nl reservoir solution.  Complexes with ligands (C20-CoA, THPPs) were grown in 737 
the presence of 3-fold molar excess of ligand over protein. Reservoir conditions 738 
leading to diffraction-quality crystals are: 0.1 M Tris pH 8.0 with 60 % v/v 739 
polypropylene glycol 400 (apo EchA6); 0.17 M ammonium sulfate, 25.5 % w/v PEG 740 
4K, 15 % v/v glycerol (EchA6:C20-CoA); 0.1 M Tris pH 8.5 with 20 % v/v ethanol 741 
(EchA6:366A); 0.6 M tri-sodium citrate cryoprotected with a 10 % glycerol additive 742 
(EchA6:059A); 0.2 M sodium chloride, 0.1 M sodium cacodylate pH 6.5, 2 M 743 
ammonium sulfate, cryoprotected with a 10 % ethylene glycol additive 744 
(EchA6:572A); 0.1 M sodium cacodylate pH 6.5, 1.0 M tri-sodium citrate 745 
cryoprotected with a 20 % glycerol additive (EchA6:951A). X-ray diffraction data 746 
were recorded at the Diamond Light Source and on our in-house X-ray source 747 
(Rigaku MicroMax 007HF, VariMax optics, Saturn 944 CCD detector). Details of the 748 
X-ray data statistics are given in Supplementary Table 5. Data were reduced using 749 
XDS, XSCALE37 and analysed using the CCP4 suite of crystallographic software38. 750 
Using M. tuberculosis EchA6 (PDB entry 3HE2) as a search model, we determined 751 
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initial phases by molecular replacement (PHASER39). The models were rebuilt and 752 
refined (COOT40, REFMAC541, PHENIX.REFINE42), using non-crystallographic 753 
symmetry restraints where the asymmetric unit contained 3 or 6 EchA6 subunits. Due 754 
to the limited resolution of the corresponding X-ray data, grouped B-factors were 755 
modelled when refining the complexes of EchA6:C20-CoA, EchA6:GSK059A and 756 
EchA6:GSK951A. Ligand geometry restraints were generated using the SKETCHER 757 
utility of CCP438. Figures of the molecular structures of EchA6 were prepared using 758 
PyMOL (www.pymol.org). Refinement statistics are reported in Supplementary 759 
Table 5. The Fo-Fc density maps (Supplementary Fig. 4) indicating the presence 760 
and structures of the ligands were generated using phases of the protein model after 761 
initial refinement of the molecular replacement solution and prior to incorporation of 762 
the ligand in the coordinate model. 763 
 764 
Intrinsic tryptophan fluorescence ligand binding assays 765 
 766 
Fluorescence binding assays of EchA6 (3.75 µM) with acyl-CoAs were conducted on 767 
a Hitachi F7000 Fluorescence Spectrophotometer using 25 mM HEPES, 10 % 768 
glycerol and 300 mM NaCl, pH 8 at 25ºC and fluorescence spectra measured at an 769 
excitation wavelength 280 nm and emission wavelength 300-400 nm with an 770 
excitation and emission slit width of 5 nm using a 500 µl crystal cuvette. Ligands 771 
were added at increasing stoichiometric ratios ranging from 0.5 to 8 times the molar 772 
concentration of protein. DMSO concentrations were maintained at <0.6 % and <2.0 773 
% in the assay mixture for acyl-CoA and THPP, respectively. Data were recorded 774 
using Hitachi FL Solutions 4.6 software and analysed in Prism 5 (GraphPad). To 775 
compare ligand binding between wild-type EchA6 and EchA6W133A, the proteins were 776 
   37 
dialysed against buffer 25 mM HEPES, 10 % glycerol and 300 mM NaCl, pH 8, 2 % 777 
DMSO (v/v). Changes of fluorescence intensities were corrected for volume 778 
expansion and for non-specific binding of DMSO.  779 
780 
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THPP target assignment reveals EchA6 as an essential fatty acid shuttle in 1 
mycobacteria 2 
 3 
Supplementary Information Guide 4 
 5 
Supplementary Figure 1. Essentiality of echA6, resistance and sensitivity to 6 
GSK951A via echA6 and mmpL3 overexpression in M. bovis BCG. (PDF, 1.3 MB) 7 
(a,b) Growth curves of ∆BCG0957 in liquid medium with or without ATc (n = 2 8 
biological replicates). One culture of ∆BCG0957 was labeled with [14C]-acetate at day 9 
15 indicated by the arrow on panel a for 24 hours with the corresponding total 10 
MAMES and FAMES isolated, and equal counts for each sample subjected to TLC 11 
and exposed to Kodak X-Omat film as shown in panel b (n = 1 technical replicate). 12 
The second culture was monitored until cell lysis was observed and is shown in the 13 
inset of panel a (n = 1 technical replicate). (c,d) [14C]-Acetate labeling of M. bovis 14 
BCG pVV16 and pVV16-echA6 strains (n = 4 biological replicates). The 15 
corresponding total MAMES and FAMES were isolated and equal counts were 16 
subjected to either TLC (c, left panel) or reverse-phase TLC (panel d) and exposed to 17 
Kodak X-Omat film (n = 1 technical replicate). Cell wall bound MAMES were 18 
isolated from M. bovis BCG pVV16 and pVV16-echA6 strains treated with GSK951A 19 
at 0.32 µM (1 × MIC, c, right panel, n = 4 biological replicates, 1 technical replicate) 20 
and equal volumes subjected to TLC and exposed to Kodak X-Omat film. (e) MIC 21 
determination of GSK951A against M. bovis BCG pVV16 and pVV16-echA6 strains 22 
in liquid medium. (f) GSK951A sensitivity of M. bovis BCG pMV261 and pMV261-23 
mmpL3 strains in liquid medium. It should be noted that the plasmids pVV16 and 24 
pMV261 used in panels e and f have different antibiotic selection markers, kanamycin 25 
   2 
and apramycin respectively, and hence have different synergy levels with THPPs. A 26 
plasmid control is always used to give a base-line MIC for THPPs in plasmid-borne 27 
overexpression studies. 28 
 29 
Supplementary Figure 2. Synthesis of total MAMES and FAMES, and cell wall 30 
bound MAMES in the presence of GSK951A, GSK540A and MmpL3 inhibitors. 31 
(PDF, 2.2 MB) 32 
 [14C]-Acetate labeling and dose-response of GSK951A, GSK540A, BM212 and 33 
SQ109 on the synthesis of FAMES and MAMES (left panel), and cell wall bound 34 
MAMES (centre panel) in M. bovis BCG. The corresponding total FAMES and 35 
MAMES, and cell wall bound MAMES were isolated, and equal counts for the former 36 
and equal volumes for the latter were subjected to TLC or reverse-phase TLC 37 
(GSK951A, right panel) and exposed to Kodak X-Omat film. The corresponding 38 
structures of GSK540A, BM212 and SQ109 are shown. 39 
 40 
Supplementary Figure 3. Lipid-[14C]-labeling experiments using GSK951A. 41 
(PDF, 4.9 MB) 42 
2D-TLC lipid profiles of M. bovis BCG (control) and GSK951A treated M. bovis 43 
BCG (1 × and 4 × MIC). Apolar and polar lipids were isolated, and equal counts for 44 
each sample subjected to TLC in solvent systems A to D1 (apolar lipids) and D2 45 
(polar lipids), and exposed to Kodak X-Omat film. PDIMs, phthiocerol 46 
dimycocerosates; TAG, triacylglycerol; MAT, multi-acylated trehaloses; F, fatty 47 
acids; GroM, monomycolylglycerol; PGL, phenolic glycolipid; GMM, glucose 48 
monomycolate; TMM, trehalose monomycolate.  49 
 50 
   3 
Supplementary Figure 4. Structural comparison of EchA6, evidence for binding 51 
of GSK951A, and comparison of the mode of binding between THPP 52 
compounds. (PDF, 549 KB) 53 
(a) Superposition of the EchA6 monomer (rainbow colored – N-terminal blue, C-54 
terminal red) and Rattus norvegicus enoyl-CoA hydratase (RnECH, grey ribbon, PDB 55 
entry 1DUB23). (b) Superposition of the active sites of RnECH (1DUB, cyan stick 56 
model) and M. tuberculosis EchA8 (3PZK, grey sticks). (c) Stereo diagram of 57 
unbiased Fo-Fc density (contour level 3.0 σ) of C20-CoA in molecule B of the 58 
EchA6:C20-CoA complex. Phases were from the initial refinement of the molecular 59 
replacement solution for this complex, prior to incorporation of the ligand in the 60 
structural model. (d) Stereo diagram of unbiased Fo-Fc density (contour level 2.5 σ) 61 
of GSK951A in molecule B of the EchA6 trimer, calculated using model phases prior 62 
to incorporation of the ligand model in the coordinates and amplitudes of the 63 
EchA6:GSK951A complex. (e-g) Superposition of GSK951A with THPP compounds 64 
GSK059A (e), GSK366A (f) and GSK572A (g). GSK059A lacks the trifluoromethyl 65 
group and has a methyl instead. (h) Unbiased Fo-Fc density (contour level 3.0 σ) of 66 
the bait compound GSK729A, calculated with model phases prior to incorporation of 67 
the ligand in the coordinates and structure factor amplitudes of the EchA6:GSK729A 68 
complex. Color coding of atoms: N, dark blue; O, red; F, pale cyan. Carbon atoms are 69 
colored according to inhibitor: GSK951A, cyan; GSK366A, grey; GSK059A, green; 70 
GSK572A, orange. 71 
 72 
Supplementary Figure 5. Predicted functional partners of EchA6 based on 73 
database mining by STRING29. (PDF, 1.0 MB) 74 
   4 
(a) Interaction network for EchA6 of M. tuberculosis H37Rv. FadB2 and FadB3, 3-75 
hydroxybutyryl-CoA dehydrogenases; FadB, fatty oxidation protein; FadD11, fatty 76 
acid-CoA ligase; AccBC, acetyl-/propionyl-CoA carboxylase β-subunit; FadE5, 77 
FadE15, FadE24, FadE25 and FadE36, acyl-CoA dehydrogenases. (b) Interaction 78 
network for EchA6 of M. leprae Br4923. B1306.06c, 3-hydroxyisobutyryl-CoA 79 
hydrolase; FadE23, putative acyl-CoA dehydrogenases; FadA and FadA4, acetyl-CoA 80 
acetyltransferases; EftB, electron transfer flavoprotein β-subunit. All other proteins as 81 
in panel a. Connecting lines are color coded as follows: green, genome 82 
neighbourhood; red, gene fusion; blue, co-occurrence; black, co-expression; 83 
turquoise, databases; yellow-green, text mining. 84 
 85 
Supplementary Figure 6. Original scans for all Western and TLC data. (PDF, 8.8 86 
MB) 87 
 88 
Supplementary Table 1. 6-plexed Chemoproteomics Experiment #1 (.xlsx, 225 89 
KB) 90 
 91 
Supplementary Table 2. 6-plexed Chemoproteomics Experiment #2 (.xlsx, 193 92 
KB) 93 
 94 
Supplementary Table 3. 6-plexed Chemoproteomics Experiment #3 (.xlsx, 184 95 
KB) 96 
 97 
Supplementary Table 4. Ligand binding for EchA6 and EchA6W133A probed by 98 
intrinsic tryptophan fluorescence. (PDF, 75.0 KB) 99 
   5 
N.D. – not determined due to failure of non-linear fitting  100 
 101 
Supplementary Table 5. Crystallographic data and refinement statistics. (PDF, 102 
88.0 KB) 103 
1) Values in parenthesis refer to the high resolution shell.  2) The Ramachandran plot 104 
distribution was calculated using Molprobity. 105 
 106 
Supplementary Table 6. EchA paralogues across mycobacterial genomes. (PDF, 107 
78.0 KB) 108 
1) EchA paralogues with conserved catalytic carboxylates required for enoyl-CoA 109 
hydratases activity in bold. 110 
 111 
Supplementary Table 7. The primers used in this study. (PDF, 51.0 KB) 112 
 113 
   
 
 
 
   
 
   
 
 
   
 
 
 
 
   
 
 
 
   
 
1Supplementary Table 2: 
6-plexed Chemoproteomics Experiment #2
Name Protein description MW no_of_Quant. 
Spectra
no_of_Quant. 
Uniq. Peptides
fold change vs 
sample 6
sum ion area peptides fold change vs 
sample 6
sum ion area peptides fold change vs 
sample 6
sum ion area peptides fold change vs 
sample 6
sum ion area peptides fold change vs 
sample 6
sum ion area peptides fold change vs 
sample 6
sum ion area peptides
BCG_0957 PUTATIVE ENOYL-COA HYDRATASE ECHA6 26029 112 25 3.3 584,436,170 340 4.4 779,484,564 340 3.62 640,389,271 340 4.03 713,406,153 340 0.19 34,856,268 340 1 176,632,181 340
BCG_0717 DNA-DIRECTED RNA POLYMERASE (BETA' CHAIN) 146710 42 40 0.81 115,893,702 77 0.87 124,513,275 77 0.66 94,378,346 77 0.9 129,054,177 77 1.17 167,282,340 77 1 143,616,796 77
BCG_2801C BIFUNCTIONAL PROTEIN POLYRIBONUCLEOTIDE 79735 33 25 0.87 147,364,550 60 0.84 143,354,793 60 0.76 129,221,064 60 0.77 130,357,722 60 0.99 168,159,585 60 1 169,721,489 60
BCG_0716 DNA-DIRECTED RNA POLYMERASE SUBUNIT BETA 129236 28 25 0.92 99,227,571 55 0.84 90,077,159 55 0.7 74,775,026 55 0.9 95,828,154 55 1.13 120,927,401 55 1 107,201,170 55
BCG_0956C PUTATIVE ACETYL-COENZYME A CARBOXYLASE C 51772 17 17 0.94 44,883,476 31 1.29 61,734,500 31 0.75 35,753,984 31 0.9 42,798,433 31 1 47,836,684 31 1 47,929,367 31
BCG_3522C PUTATIVE DNA-DIRECTED RNA POLYMERASE (ALP 37706 16 13 0.91 74,985,115 32 0.99 80,420,382 32 0.89 72,501,204 32 0.96 78,128,799 32 1.03 84,533,163 32 1 81,680,675 32
BCG_3523C PUTATIVE 30S RIBOSOMAL PROTEIN S4 RPSD 23476 15 12 0.89 93,779,223 21 1.06 111,235,028 21 0.92 97,329,662 21 1.02 107,288,242 21 1.03 108,809,481 21 1 105,554,752 21
BCG_0389 PUTATIVE CHAPERONE PROTEIN DNAK 66831 14 14 0.72 31,682,011 34 1.08 47,162,829 34 0.91 39,628,293 34 0.93 40,890,426 34 0.86 38,086,016 34 1 43,891,533 34
BCG_1812C HYPOTHETICAL INTEGRAL MEMBRANE PROTEIN 63512 14 14 0.74 25,729,976 31 0.94 32,552,596 31 0.81 27,994,773 31 0.92 31,924,698 31 1 34,756,593 31 1 34,764,296 31
BCG_2464C PUTATIVE RIBONUCLEASE E RNE 103390 13 11 1.16 28,300,383 28 1.15 28,226,678 28 0.93 22,680,779 28 0.99 24,389,859 28 1.41 34,361,847 28 1 24,483,122 28
BCG_1357 PUTATIVE TRANSCRIPTION TERMINATION FACTO 65133 12 12 0.68 19,876,895 32 0.67 19,644,476 32 0.65 18,978,875 32 0.78 22,865,620 32 1.11 32,777,350 32 1 29,403,035 32
BCG_1668 PUTATIVE RIBOSOMAL PROTEIN S1 RPSA 53232 12 9 0.67 31,267,981 24 0.94 44,262,614 24 0.98 46,213,597 24 0.85 39,405,984 24 1.13 52,580,500 24 1 46,991,599 24
BCG_0437C PUTATIVE ACYL-COA DEHYDROGENASE FADE7 42297 11 9 0.85 72,867,895 16 1.01 86,587,245 16 0.87 74,909,461 16 1.21 103,918,626 16 0.99 85,183,072 16 1 85,974,492 16
BCG_3007C PUTATIVE DNA-BINDING PROTEIN HU HOMOLOG H 21292 10 6 1.72 154,913,920 20 1.24 111,374,044 20 0.85 76,428,523 20 1.14 102,188,980 20 1.17 104,899,060 20 1 89,894,527 20
BCG_3238 PUTATIVE ATP-DEPENDENT RNA HELICASE RHLE 56703 10 10 0.92 27,581,006 17 1.01 29,995,584 17 0.95 28,532,792 17 0.99 29,450,561 17 1.37 40,982,989 17 1 29,821,454 17
BCG_3524C PUTATIVE 30S RIBOSOMAL PROTEIN S11 RPSK 14771 8 6 1.02 74,808,931 13 1.11 81,029,220 13 1.01 74,437,798 13 1.3 95,093,512 13 1.21 88,657,921 13 1 73,614,113 13
BCG_0757 PUTATIVE 30S RIBOSOMAL PROTEIN S3 RPSC 30020 8 8 1 25,777,222 22 1.44 38,198,563 22 1.35 34,856,935 22 1.69 44,077,197 22 1.43 36,857,830 22 1 25,843,896 22
BCG_3488C 10 KDA CHAPERONIN GROES 10804 8 8 1.98 82,438,220 9 2.37 99,127,695 9 1.42 59,145,809 9 1.35 55,864,346 9 1.82 75,887,902 9 1 41,687,542 9
BCG_2859C PUTATIVE TRANSLATION INITIATION FACTOR IF-2 94041 8 7 1.05 17,392,180 23 1.04 17,080,778 23 0.95 15,553,029 23 1.47 24,267,357 23 1.85 30,516,723 23 1 16,521,695 23
BCG_0479 60 KDA CHAPERONIN 2 GROEL2 56727 7 7 0.56 18,020,223 29 0.59 18,975,455 29 0.51 16,217,551 29 0.87 27,753,061 29 1.14 36,644,112 29 1 32,285,669 29
BCG_2447 ALKYL HYDROPEROXIDE REDUCTASE C PROTEIN 21566 6 6 1.05 22,048,865 17 1.13 23,606,614 17 1.02 21,412,938 17 1.08 22,667,928 17 0.89 18,483,061 17 1 20,847,507 17
BCG_0690 PUTATIVE 50S RIBOSOMAL PROTEIN L1 RPLA 24726 6 4 0.89 8,981,629 13 1.27 12,812,919 13 0.8 8,113,995 13 1.19 11,947,352 13 0.91 9,142,272 13 1 10,104,093 13
BCG_0280C PUTATIVE 3-OXOACYL-ACYL-CARRIER PROTEIN] R 46830 6 6 0.88 11,046,936 10 0.55 6,842,445 10 0.43 5,353,855 10 1.19 15,035,912 10 1.04 13,043,185 10 1 12,571,801 10
BCG_0086 PUTATIVE 30S RIBOSOMAL PROTEIN S18-1 RPSR1 9543 6 6 1.12 28,873,213 10 0.97 24,303,134 10 0.87 22,231,972 10 1.41 36,359,363 10 1.15 29,035,572 10 1 25,661,378 10
BCG_0752 PUTATIVE 50S RIBOSOMAL PROTEIN L4 RPLD 23743 6 6 0.76 12,963,165 12 0.98 16,747,963 12 1.09 18,466,335 12 0.98 16,874,198 12 1.26 21,576,211 12 1 17,140,946 12
BCG_3269C PUTATIVE PREPROTEIN TRANSLOCASE SUBUNIT 106022 6 6 1.04 5,991,307 16 0.8 4,667,807 16 0.82 4,707,328 16 1.04 5,998,369 16 1.31 7,652,388 16 1 5,785,030 16
BCG_3863C PUTATIVE FATTY-ACID-COA LIGASE FADD32 69260 5 5 1 5,763,981 12 0.74 4,265,874 12 1.01 5,858,425 12 0.99 5,711,968 12 0.78 4,459,127 12 1 5,783,282 12
BCG_3008C PUTATIVE 3-ISOPROPYLMALATE DEHYDRATASE S 21780 5 5 0.84 6,810,685 5 0.93 7,533,575 5 0.76 6,181,259 5 0.97 7,903,264 5 0.87 7,095,900 5 1 8,126,149 5
BCG_1595 PUTATIVE FATTY ACYL-COA REDUCTASE 36821 5 5 0.92 20,096,155 9 0.81 17,693,711 9 0.71 15,488,336 9 1.23 26,906,753 9 1.04 22,635,061 9 1 21,813,354 9
BCG_0516 HEPARIN BINDING HEMAGGLUTININ HBHA 21534 5 5 0.87 17,425,277 9 0.97 19,428,798 9 0.73 14,551,654 9 0.89 17,836,914 9 1.11 22,141,638 9 1 20,004,495 9
BCG_0780 HYPOTHETICAL PROTEIN 25980 5 5 1.07 13,375,046 9 1.29 16,089,333 9 0.8 10,012,397 9 1.15 14,373,935 9 1.18 14,776,931 9 1 12,517,917 9
BCG_3704C DNA TOPOISOMERASE I TOPA 102370 5 5 1.08 12,079,166 26 1.11 12,184,585 26 0.82 9,230,913 26 1.02 11,376,411 26 1.22 13,679,046 26 1 11,233,520 26
BCG_1680 PUTATIVE INITIATION FACTOR IF-3 INFC 22349 5 5 1.06 16,060,497 10 0.78 11,867,874 10 0.84 12,705,926 10 1.11 16,778,180 10 1.3 19,706,601 10 1 15,164,761 10
BCG_3127C PUTATIVE CELL DIVISION ATP-BINDING PROTEIN F 25596 5 5 1.03 6,357,925 9 0.85 5,208,584 9 1.21 7,477,020 9 1.35 8,289,120 9 1.41 8,664,997 9 1 6,158,589 9
BCG_0084 PUTATIVE 30S RIBOSOMAL PROTEIN S6 RPSF 10935 4 4 0.85 2,489,221 7 1.38 4,016,916 7 0.69 1,997,838 7 1.42 4,130,902 7 0.84 2,451,107 7 1 2,914,120 7
BCG_3662C PUTATIVE LSR2 PROTEIN PRECURSOR 12098 4 4 0.99 4,728,361 10 0.85 4,058,255 10 1.06 5,080,533 10 1.15 5,508,663 10 0.89 4,282,565 10 1 4,791,310 10
BCG_3904 PUTATIVE BACTERIOFERRITIN BFRB 20442 4 3 1 6,603,042 4 1.12 7,360,748 4 0.91 6,021,977 4 1.19 7,856,254 4 0.96 6,348,024 4 1 6,587,410 4
BCG_0750 30S RIBOSOMAL PROTEIN S10 RPSJ (TRANSCRIPT 11431 4 3 1.23 13,129,480 7 1.07 11,404,262 7 0.95 10,130,186 7 1.19 12,771,723 7 1.05 11,231,300 7 1 10,700,139 7
BCG_0751 PUTATIVE 50S RIBOSOMAL PROTEIN L3 RPLC 23090 4 4 1.25 10,688,345 5 0.88 7,551,018 5 0.91 7,804,145 5 0.7 6,014,855 5 1.11 9,476,962 5 1 8,545,865 5
BCG_2911C PUTATIVE 30S RIBOSOMAL PROTEIN S2 RPSB 31089 4 4 0.85 5,996,733 10 0.89 6,253,702 10 0.9 6,336,680 10 1.06 7,500,075 10 1.26 8,884,240 10 1 7,046,498 10
BCG_3853 PUTATIVE SHORT-CHAIN TYPE DEHYDROGENASE 27469 4 3 1.16 2,655,748 4 0.31 717,195 4 0.75 1,716,898 4 1.18 2,693,003 4 1.3 2,957,521 4 1 2,281,981 4
BCG_2243 HYPOTHETICAL PROTEIN 56332 4 4 1.67 2,713,499 7 1.84 2,996,500 7 0.42 678,269 7 1.78 2,892,943 7 1.56 2,538,273 7 1 1,626,615 7
BCG_1676 EXCINUCLEASE ABC, SUBUNIT A UVRA 106132 3 3 0.19 380,243 10 0.68 1,338,692 10 0.27 538,015 10 0.38 747,802 10 0.32 627,849 10 1 1,963,700 10
BCG_0504C HYPOTHETICAL PROTEIN 21305 3 3 1.01 9,633,368 3 0.63 5,985,824 3 0.82 7,801,373 3 1.36 12,957,745 3 0.77 7,400,899 3 1 9,548,433 3
BCG_2768C HYPOTHETICAL PROTEIN 59532 3 3 0.72 8,076,259 3 0.8 9,027,629 3 0.54 6,096,935 3 0.82 9,177,268 3 0.94 10,604,054 3 1 11,241,319 3
BCG_0183 PUTATIVE ALDEHYDE DEHYDROGENASE (NAD+) D 55035 3 3 0.62 3,569,500 13 1.07 6,110,749 13 0.88 5,034,746 13 0.73 4,150,407 13 0.95 5,452,738 13 1 5,715,073 13
BCG_3487C 60 KDA CHAPERONIN 1 GROEL1 55877 3 3 0.84 3,569,591 8 0.46 1,939,798 8 0.42 1,794,534 8 0.82 3,469,544 8 0.99 4,188,503 8 1 4,241,954 8
BCG_2962C PUTATIVE MULTIFUNCTIONAL MYCOCEROSIC ACI 224396 3 3 0.71 4,148,478 11 1.13 6,549,409 11 0.53 3,108,438 11 0.87 5,045,389 11 1.02 5,941,255 11 1 5,814,896 11
BCG_3521C PUTATIVE 50S RIBOSOMAL PROTEIN L17 RPLQ 19475 3 3 0.79 5,605,734 4 0.93 6,561,208 4 0.86 6,082,612 4 0.92 6,494,061 4 1.15 8,127,840 4 1 7,073,952 4
BCG_0767 PUTATIVE 30S RIBOSOMAL PROTEIN S14 RPSN1 6825 3 1 2.19 5,437,546 4 2.22 5,510,842 4 1.45 3,600,908 4 2.69 6,678,362 4 1.43 3,537,849 4 1 2,477,486 4
BCG_2607C ADENINE PHOSPHORIBOSYLTRANSFERASE APT 23246 3 3 1.03 3,956,989 5 1.68 6,490,680 5 0.78 3,018,986 5 1.23 4,743,091 5 1.46 5,613,897 5 1 3,856,162 5
BCG_0771 PUTATIVE 30S RIBOSOMAL PROTEIN S5 RPSE 22888 3 3 1.73 22,420,008 12 1.09 14,100,508 12 0.96 12,473,539 12 1.43 18,442,270 12 1.8 23,258,977 12 1 12,941,454 12
BCG_2261 MEROMYCOLATE EXTENSION ACYL CARRIER PRO 12524 3 2 2.4 20,267,246 4 3.43 28,950,302 4 1.63 13,767,254 4 2.37 19,999,185 4 2.08 17,531,802 4 1 8,429,469 4
BCG_0023C PUTATIVE CHROMOSOME PARTITIONING PROTEIN 37018 2 2 0.95 1,717,706 8 0.62 1,134,293 8 0 0 8 1.82 3,304,326 8 0 0 8 1 1,816,794 8
BCG_0622 HYPOTHETICAL PROTEIN TB27 3 27343 2 2 0.87 866,042 3 0 0 3 2.52 2,523,344 3 0.93 935,754 3 0 0 3 1 1,001,119 3
BCG_0772 PUTATIVE 50S RIBOSOMAL PROTEIN L30 RPMD 7347 2 2 1.94 873,271 2 1.48 667,318 2 2.11 953,019 2 2.28 1,027,885 2 0 0 2 1 450,487 2
BCG_3270C HYPOTHETICAL PROTEIN 24567 2 2 1.86 2,082,763 4 1.16 1,306,045 4 0.43 487,281 4 1.97 2,212,882 4 0 0 4 1 1,121,868 4
BCG_2183C HYPOTHETICAL PROTEIN 15912 2 2 0.38 585,851 5 0.8 1,213,064 5 1.05 1,605,428 5 1.5 2,280,626 5 0.11 172,009 5 1 1,522,500 5
BCG_0770 PUTATIVE 50S RIBOSOMAL PROTEIN L18 RPLR 13184 2 2 0.65 5,269,742 4 0.69 5,581,176 4 0.7 5,693,091 4 0.69 5,598,605 4 0.51 4,112,493 4 1 8,105,754 4
BCG_0963 HYPOTHETICAL PROTEIN 27627 2 2 0.87 3,624,397 5 0.72 2,976,761 5 0.76 3,156,759 5 0.88 3,631,703 5 0.59 2,440,274 5 1 4,142,748 5
BCG_0701 PUTATIVE 50S RIBOSOMAL PROTEIN L7/L12 RPLL 13440 2 2 0.3 622,998 4 0.85 1,746,389 4 1.64 3,374,214 4 0.56 1,148,538 4 0.68 1,390,819 4 1 2,059,831 4
BCG_3009C PUTATIVE 3-ISOPROPYLMALATE DEHYDRATASE L 50199 2 2 0.47 2,661,047 7 0.76 4,327,239 7 0.83 4,705,067 7 0.8 4,523,338 7 0.7 3,981,023 7 1 5,676,117 7
BCG_3915 PUTATIVE HISTONE-LIKE PROTEIN HNS 13823 2 2 0.84 3,553,100 2 0.87 3,664,132 2 0.72 3,042,144 2 1.02 4,299,548 2 0.81 3,429,665 2 1 4,230,022 2
BCG_3142 PUTATIVE THIOSULFATE SULFURTRANSFERASE C 35999 2 2 0.84 6,073,809 6 0.96 6,927,817 6 0.95 6,852,531 6 1.11 8,035,866 6 0.82 5,952,770 6 1 7,225,872 6
BCG_1798 PUTATIVE CUTINASE CUT1 21999 2 1 0.96 3,018,382 2 0.91 2,883,511 2 0.83 2,607,175 2 0.96 3,016,357 2 0.83 2,622,816 2 1 3,151,752 2
BCG_1964 PUTATIVE ACYL-COA LIGASE FADD31 66310 2 2 0.51 1,758,351 4 0.67 2,335,956 4 0.81 2,828,664 4 0.59 2,054,499 4 0.89 3,094,959 4 1 3,481,750 4
BCG_0734 PUTATIVE ELONGATION FACTOR TU TUF (EF-TU) 43594 2 2 0.69 4,453,905 4 0.65 4,205,096 4 0.55 3,534,045 4 0.27 1,766,358 4 1.05 6,811,165 4 1 6,480,318 4
BCG_2462C PUTATIVE 50S RIBOSOMAL PROTEIN L21 RPLU 11151 2 2 0.5 3,544,106 2 0.69 4,878,585 2 1 7,070,810 2 0.87 6,091,105 2 1.14 8,039,184 2 1 7,041,483 2
BCG_1449 PUTATIVE INTEGRATION HOST FACTOR MIHF 20835 2 2 0.85 6,398,985 4 1.11 8,327,887 4 0.85 6,357,036 4 2.07 15,465,283 4 1.28 9,619,441 4 1 7,483,942 4
BCG_2017 HYPOTHETICAL PROTEIN 59895 2 2 0.99 1,210,970 5 1.27 1,550,028 5 0.53 648,510 5 1.31 1,602,316 5 1.61 1,963,596 5 1 1,219,330 5
BCG_0050C HYPOTHETICAL PROTEIN TB39 8 56003 2 2 1.02 1,095,398 7 2.02 2,164,298 7 2.04 2,180,517 7 2.49 2,661,116 7 2.1 2,247,070 7 1 1,069,946 7
BCG_3118C PUTATIVE OXIDOREDUCTASE 34649 2 2 n.d. 1,023,679 2 n.d. 0 2 n.d. 0 2 n.d. 750,346 2 n.d. 681,318 2 n.d. 0 2
sample 3
immobilized cpd: GSK729, 0.05 mM
rebinding of nonbound fraction from sample 1
sample 3
immobilized cpd: GSK729, 0.05 mM
rebinding of nonbound fraction from sample 2
sample 5
immobilized cpd: GSK729,  0.05 mM
competing cpd:  GSK729 100 µM
sample 6
immobilized cpd: GSK729, 0.05 mM
competing cpd:  GSK729 10 µM
sample 1
immobilized cpd: GSK729, 0.05 mM
sample 2
immobilized cpd: GSK729, 0.05 mM
(replicate of sample 1)
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sample 6
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BCG_0957 PUTATIVE ENOYL-COA HYDRATASE ECHA6 26029 344 26 0.08 22,561,852 524 0.84 227,297,647 524 11.09 1 272,611,013 524 0.49 12,115,720 524 0.52 12,721,330 524 1 24,576,703 524
BCG_1367 PUTATIVE ATP SYNTHASE DELTA CHAIN ATPH 48806 2 1 0.58 32,943 4 0.46 26,093 4 2.27 1 57,247 4 1.16 29,111 4 1.95 49,022 4 1 25,192 4
BCG_3238 PUTATIVE ATP-DEPENDENT RNA HELICASE RHLE 56703 26 20 1.11 15,628,958 35 1.18 16,591,469 35 2.19 1 14,006,490 35 2.56 16,361,831 35 1.62 10,363,466 35 1 6,390,235 35
BCG_0963 HYPOTHETICAL PROTEIN 27627 3 3 0.87 1,816,722 3 1.81 3,794,322 3 2.06 1 2,091,866 3 0.31 312,711 3 2.05 2,079,214 3 1 1,015,038 3
BCG_2261 MEROMYCOLATE EXTENSION ACYL CARRIER PROTEI 12524 2 1 1.49 380,655 2 1.19 302,892 2 1.94 1 254,747 2 1.64 215,222 2 1.6 209,948 2 1 131,455 2
BCG_0751 PUTATIVE 50S RIBOSOMAL PROTEIN L3 RPLC 23090 15 12 1.4 10,675,857 18 1.48 11,327,314 18 1.89 1 7,623,841 18 2.44 9,878,390 18 1.64 6,625,638 18 1 4,039,291 18
BCG_3965 HYPOTHETICAL PROTEIN 27171 10 10 1.31 7,664,819 10 1.28 7,496,556 10 1.74 1 5,874,225 10 2.25 7,560,717 10 1.47 4,957,715 10 1 3,381,993 10
BCG_0760 PUTATIVE 50S RIBOSOMAL PROTEIN S17 RPSQ 14872 4 3 1.17 4,988,692 4 1.42 6,067,778 4 1.68 1 4,260,958 4 1.9 4,824,421 4 1.43 3,635,661 4 1 2,541,184 4
BCG_1313 PUTATIVE COLD-SHOCK DEAD-BOX PROTEIN A HOMO 61421 3 3 1.09 1,270,986 5 1.26 1,467,684 5 1.59 1 1,164,843 5 1.59 1,169,044 5 1.5 1,097,041 5 1 733,016 5
BCG_1624 HYPOTHETICAL PROTEIN 18100 4 4 1.03 1,953,733 7 0.98 1,861,725 7 1.58 1 1,898,355 7 1.53 1,835,953 7 1.5 1,800,512 7 1 1,200,192 7
BCG_2768C HYPOTHETICAL PROTEIN 59532 10 10 0.84 7,837,771 10 0.79 7,356,198 10 1.52 1 9,350,016 10 1.38 8,399,679 10 1.05 6,416,461 10 1 6,137,718 10
BCG_3525C PUTATIVE 30S RIBOSOMAL PROTEIN S13 RPSM 14351 21 17 1 18,260,366 33 1.09 20,013,882 33 1.52 1 18,195,430 33 1.5 17,986,864 33 1.17 13,992,606 33 1 11,960,179 33
BCG_2229 PUTATIVE AMINOPEPTIDASE PEPB 53447 4 4 0.76 2,332,491 6 0.78 2,387,504 6 1.42 1 3,050,887 6 1.4 3,018,078 6 0.99 2,123,093 6 1 2,155,107 6
BCG_3142 PUTATIVE THIOSULFATE SULFURTRANSFERASE CYSA 35999 4 4 0.79 2,740,714 8 0.63 2,167,615 8 1.41 1 3,451,566 8 1.16 2,825,778 8 1.86 4,543,703 8 1 2,440,123 8
BCG_2801C BIFUNCTIONAL PROTEIN POLYRIBONUCLEOTIDE NUC 79735 79 43 0.91 52,271,945 116 0.82 46,871,956 116 1.41 1 57,568,748 116 1.3 52,870,601 116 1 40,815,704 116 1 40,756,167 116
BCG_0780 HYPOTHETICAL PROTEIN 25980 3 3 0.78 2,581,717 4 0.92 3,041,232 4 1.41 1 3,305,621 4 1.09 2,553,882 4 0.97 2,275,123 4 1 2,342,153 4
BCG_0437C PUTATIVE ACYL-COA DEHYDROGENASE FADE7 42297 22 17 0.86 17,989,359 30 0.84 17,564,499 30 1.40 1 20,864,561 30 1.45 21,834,552 30 0.98 14,630,595 30 1 14,909,916 30
BCG_2464C PUTATIVE RIBONUCLEASE E RNE 103390 38 32 1.47 38,754,206 55 1.11 29,323,055 55 1.38 1 26,506,052 55 1.76 33,801,397 55 1.34 25,693,060 55 1 19,230,559 55
BCG_2550 HYPOTHETICAL PROTEIN 50192 8 8 1.11 7,102,687 9 1.14 7,245,925 9 1.38 1 6,364,650 9 1.63 7,549,463 9 1.3 6,023,058 9 1 4,627,183 9
BCG_0689 PUTATIVE 50S RIBOSOMAL PROTEIN L11 RPLK 15003 12 11 0.98 10,898,148 12 1.07 12,002,970 12 1.37 1 11,189,280 12 1.14 9,342,310 12 1 8,210,883 12 1 8,175,776 12
BCG_3009C PUTATIVE 3-ISOPROPYLMALATE DEHYDRATASE LARG 50199 4 4 0.78 1,354,743 6 0.57 986,181 6 1.37 1 1,737,418 6 1.11 1,401,610 6 1 1,275,598 6 1 1,270,764 6
BCG_0956C PUTATIVE ACETYL-COENZYME A CARBOXYLASE CAR 51772 18 14 0.92 8,997,565 23 0.89 8,679,435 23 1.35 1 9,727,810 23 1.43 10,291,475 23 1.03 7,394,628 23 1 7,190,980 23
BCG_0516 HEPARIN BINDING HEMAGGLUTININ HBHA 21534 5 5 1 6,010,458 9 1 6,026,653 9 1.35 1 6,024,311 9 1.49 6,630,503 9 1.23 5,524,738 9 1 4,457,046 9
BCG_2800C PUTATIVE ZINC PROTEASE PEPR 47072 9 8 1.07 4,066,556 11 1.16 4,450,095 11 1.34 1 3,813,531 11 1.54 4,369,064 11 1.21 3,434,410 11 1 2,849,518 11
BCG_3904 PUTATIVE BACTERIOFERRITIN BFRB 20442 4 3 0.97 3,178,911 4 0.9 2,959,060 4 1.32 1 3,278,110 4 0.89 2,201,259 4 0.97 2,411,489 4 1 2,478,522 4
BCG_0389 PUTATIVE CHAPERONE PROTEIN DNAK 66831 22 19 0.92 26,642,757 42 0.73 21,230,793 42 1.32 1 28,963,178 42 1.12 24,670,358 42 1 21,974,176 42 1 21,988,061 42
BCG_0701 PUTATIVE 50S RIBOSOMAL PROTEIN L7/L12 RPLL (SA1 13440 9 8 1.22 11,697,068 10 1.28 12,130,847 10 1.30 1 9,557,224 10 1.04 7,598,097 10 1.22 9,019,248 10 1 7,332,765 10
BCG_3277C PUTATIVE ADENOSYLHOMOCYSTEINASE SAHH 54324 5 5 1.44 5,432,753 9 0.94 3,555,292 9 1.30 1 3,787,110 9 0.92 2,679,529 9 1.18 3,435,480 9 1 2,923,280 9
BCG_0700 PUTATIVE 50S RIBOSOMAL PROTEIN L10 RPLJ 18478 13 12 1 12,412,153 17 1.15 14,206,782 17 1.29 1 12,327,374 17 1.04 9,951,194 17 0.96 9,115,494 17 1 9,545,845 17
BCG_1812C HYPOTHETICAL INTEGRAL MEMBRANE PROTEIN 63512 40 28 0.91 21,765,889 49 0.79 18,959,698 49 1.29 1 23,862,901 49 1.2 22,297,962 49 1.18 22,275,268 49 1 18,565,322 49
BCG_0929 HYPOTHETICAL PROTEIN 27469 3 2 0.64 596,200 3 0.67 622,696 3 1.28 1 934,459 3 0.96 702,673 3 0.64 470,289 3 1 732,563 3
BCG_0773 PUTATIVE 50S RIBOSOMAL PROTEIN L15 RPLO 15521 8 8 1.49 6,540,582 12 1.34 5,930,384 12 1.25 1 4,316,657 12 1.6 5,579,746 12 1.17 4,095,609 12 1 3,451,596 12
BCG_2371C PUTATIVE GLYCYL-TRNA SYNTHETASE GLYS 52938 13 12 0.81 9,965,212 20 0.87 10,709,397 20 1.24 1 12,315,657 20 1.15 11,435,330 20 1.01 9,943,903 20 1 9,897,397 20
BCG_2237 GLUTAMINE SYNTHETASE GLNA1 53570 4 4 1.19 4,614,839 7 1.02 3,925,938 7 1.24 1 3,864,811 7 0.97 3,027,127 7 1.12 3,486,681 7 1 3,116,077 7
BCG_0758 PUTATIVE 50S RIBOSOMAL PROTEIN L16 RPLP 15692 8 6 2.03 4,823,549 11 2.02 4,835,082 11 1.23 1 2,429,915 11 2.72 5,356,343 11 1.51 2,978,556 11 1 1,974,731 11
BCG_0732 PUTATIVE 30S RIBOSOMAL PROTEIN S7 RPSG 17600 18 16 1.02 13,841,494 28 1.13 15,580,505 28 1.23 1 13,751,663 28 1.16 12,937,735 28 0.92 10,208,127 28 1 11,196,927 28
BCG_2859C PUTATIVE TRANSLATION INITIATION FACTOR IF-2 INFB 94041 25 24 1.23 22,066,124 38 1.06 18,863,769 38 1.22 1 17,870,667 38 1.51 21,972,264 38 1.33 19,411,761 38 1 14,610,322 38
BCG_0227 HYPOTHETICAL PROTEIN 10365 2 2 0.68 1,351,694 3 0.95 1,871,713 3 1.22 1 1,978,796 3 0.84 1,354,869 3 0.86 1,393,158 3 1 1,618,368 3
BCG_3508C PUTATIVE 30S RIBOSOMAL PROTEIN S9 RPSI 16436 7 7 1.32 7,019,943 10 1.77 9,439,799 10 1.22 1 5,343,784 10 1.61 6,938,039 10 1.48 6,441,238 10 1 4,370,956 10
BCG_2461C PUTATIVE 50S RIBOSOMAL PROTEIN L27 RPMA 8968 4 4 1.34 5,165,073 5 1.39 5,349,935 5 1.22 1 3,849,050 5 1.62 5,114,387 5 1.25 3,937,725 5 1 3,152,236 5
BCG_1357 PUTATIVE TRANSCRIPTION TERMINATION FACTOR RH 65133 24 20 0.94 16,545,771 31 0.87 15,381,229 31 1.22 1 17,528,236 31 1.14 16,332,870 31 1.03 14,682,035 31 1 14,406,138 31
BCG_3522C PUTATIVE DNA-DIRECTED RNA POLYMERASE (ALPHA 37706 10 7 0.99 5,567,630 14 1.01 5,698,760 14 1.21 1 5,666,866 14 1.04 4,841,164 14 1.08 5,049,631 14 1 4,667,735 14
BCG_2744 HYPOTHETICAL ALANINE AND ARGININE RICH PROTE 49796 2 2 0.94 2,111,825 3 0.87 1,962,867 3 1.21 1 2,251,046 3 1.12 2,087,952 3 1.01 1,879,355 3 1 1,861,575 3
BCG_0753 PUTATIVE 50S RIBOSOMAL PROTEIN L23 RPLW 10958 8 7 1.09 4,724,966 10 1.35 5,816,545 10 1.21 1 4,315,111 10 1.26 4,490,710 10 1.13 4,036,410 10 1 3,573,696 10
BCG_0613 PUTATIVE CYTOCHROME P450 135B1 CYP135B1 50760 2 2 0.79 573,066 6 0.76 554,538 6 1.20 1 729,624 6 1.48 893,309 6 1.27 765,958 6 1 605,588 6
BCG_3118C PUTATIVE OXIDOREDUCTASE 34649 4 3 0.56 564,190 5 0.88 880,386 5 1.20 1 1,000,700 5 0.85 706,057 5 0.75 627,091 5 1 832,315 5
BCG_0769 PUTATIVE 50S RIBOSOMAL PROTEIN L6 RPLF 19377 5 5 1.05 6,804,244 9 1.16 7,521,234 9 1.20 1 6,511,404 9 1.07 5,818,001 9 1.15 6,269,088 9 1 5,443,433 9
BCG_2112C PUTATIVE ATP-DEPENDENT DNA HELICASE HELY 99636 20 18 1.05 12,919,583 29 0.85 10,365,290 29 1.19 1 12,292,147 29 1.2 12,330,655 29 0.97 9,950,431 29 1 10,305,243 29
BCG_2842C HYPOTHETICAL PROTEIN 91047 2 2 0.86 1,319,639 8 0.73 1,119,643 8 1.18 1 1,538,531 8 0.97 1,256,390 8 0.95 1,239,447 8 1 1,300,814 8
BCG_2930C PUTATIVE 30S RIBOSOMAL PROTEIN S16 RPSP 17437 5 4 1.37 2,044,595 8 1.71 2,587,541 8 1.17 1 1,506,379 8 1.49 1,907,296 8 1.69 2,160,949 8 1 1,288,521 8
BCG_1668 PUTATIVE RIBOSOMAL PROTEIN S1 RPSA 53232 39 30 0.96 36,075,789 45 0.86 32,301,446 45 1.17 1 37,782,860 45 1.1 35,579,990 45 1.01 32,665,919 45 1 32,346,561 45
BCG_0757 PUTATIVE 30S RIBOSOMAL PROTEIN S3 RPSC 30020 29 23 1.15 20,937,601 38 1.27 23,107,598 38 1.17 1 18,276,014 38 1.72 27,074,385 38 1.4 22,026,033 38 1 15,686,041 38
BCG_1947C CATALASE-PEROXIDASE-PEROXYNITRITASE T KATG 80562 2 2 1.1 857,718 2 0.81 634,849 2 1.14 1 780,604 2 1.01 690,945 2 0.97 663,829 2 1 685,885 2
BCG_3008C PUTATIVE 3-ISOPROPYLMALATE DEHYDRATASE SMA 21780 4 3 0.94 1,310,163 4 0.89 1,236,237 4 1.12 1 1,388,789 4 0.84 1,040,808 4 0.86 1,068,104 4 1 1,235,320 4
BCG_1676 EXCINUCLEASE ABC, SUBUNIT A UVRA 106132 17 15 0.98 10,811,474 20 0.81 8,941,967 20 1.12 1 11,071,180 20 1.31 12,922,185 20 1.03 10,187,747 20 1 9,879,593 20
BCG_2135C PUTATIVE RNA METHYLTRANSFERASE 30123 6 6 1.45 6,509,639 6 1.36 6,069,361 6 1.11 1 4,487,631 6 1.54 6,231,228 6 1.24 4,991,770 6 1 4,041,563 6
BCG_0754 PUTATIVE 50S RIBOSOMAL PROTEIN L2 RPLB 30577 12 9 1.23 7,579,456 22 1.75 10,913,730 22 1.11 1 6,218,048 22 1.01 5,676,208 22 1.78 9,986,124 22 1 5,602,194 22
BCG_1389C PUTATIVE GLUCANASE GLGE 78640 2 2 1.01 428,215 2 0.84 355,613 2 1.10 1 422,510 2 0.79 302,974 2 0.82 312,832 2 1 382,571 2
BCG_0690 PUTATIVE 50S RIBOSOMAL PROTEIN L1 RPLA 24726 20 15 1.14 19,793,695 24 1.14 19,737,280 24 1.09 1 17,238,732 24 1.22 19,331,895 24 1.01 16,057,050 24 1 15,837,968 24
BCG_3524C PUTATIVE 30S RIBOSOMAL PROTEIN S11 RPSK 14771 7 6 0.83 6,671,248 9 1.15 9,280,505 9 1.09 1 8,170,040 9 1.29 9,607,126 9 1.08 8,097,439 9 1 7,507,668 9
BCG_3521C PUTATIVE 50S RIBOSOMAL PROTEIN L17 RPLQ 19475 5 4 0.83 4,173,078 8 1 5,069,807 8 1.09 1 5,169,765 8 1.21 5,764,551 8 1.26 6,004,958 8 1 4,754,621 8
BCG_3704C DNA TOPOISOMERASE I TOPA 102370 15 11 1.02 6,934,540 28 0.92 6,222,581 28 1.07 1 6,745,958 28 1.14 7,152,820 28 1.06 6,600,118 28 1 6,291,654 28
BCG_2843C HYPOTHETICAL PROTEIN 34432 3 3 0.9 1,919,446 6 0.94 1,997,631 6 1.07 1 2,125,236 6 1.05 2,081,709 6 0.89 1,772,943 6 1 1,984,763 6
BCG_0510C MYCOLIC ACID SYNTHASE PCAA 33028 2 2 0.97 1,665,742 3 0.69 1,175,984 3 1.07 1 1,709,125 3 1.1 1,757,500 3 0.92 1,475,331 3 1 1,597,138 3
BCG_2607C ADENINE PHOSPHORIBOSYLTRANSFERASE APT 23246 4 4 1.08 3,257,115 5 1.2 3,638,814 5 1.07 1 3,023,967 5 1.54 4,359,919 5 1.3 3,668,330 5 1 2,831,654 5
BCG_0770 PUTATIVE 50S RIBOSOMAL PROTEIN L18 RPLR 13184 8 7 1.03 8,215,926 10 1.06 8,418,396 10 1.06 1 7,939,271 10 1.07 8,015,276 10 0.98 7,291,690 10 1 7,462,323 10
BCG_0050C HYPOTHETICAL PROTEIN TB39 8 56003 4 4 0.81 2,093,896 5 0.67 1,723,078 5 1.06 1 2,583,908 5 1 2,434,164 5 0.85 2,071,829 5 1 2,439,383 5
BCG_0200 HYPOTHETICAL PROTEIN TB18 5 17738 2 2 0.84 695,555 4 0.82 680,398 4 1.06 1 826,178 4 0.81 634,784 4 0.79 617,881 4 1 781,024 4
BCG_1453 PUTATIVE S-ADENOSYLMETHIONINE SYNTHETASE ME 43019 2 2 1.35 1,183,039 2 0.86 752,647 2 1.06 1 879,515 2 0.71 592,691 2 0.84 697,315 2 1 833,555 2
BCG_1072C PUTATIVE 50S RIBOSOMAL PROTEIN L25 RPLY 22441 2 1 0.68 176,176 3 0.73 191,470 3 1.05 1 260,758 3 0.51 126,830 3 0.65 161,810 3 1 249,496 3
BCG_1472C PUTATIVE LIPOPROTEIN LPRG 24548 3 3 0.91 2,032,290 5 0.88 1,959,113 5 1.04 1 2,229,651 5 0.88 1,869,156 5 0.93 1,980,264 5 1 2,136,484 5
BCG_0716 DNA-DIRECTED RNA POLYMERASE SUBUNIT BETA RP 129236 24 21 1.17 19,140,354 32 0.92 14,935,702 32 1.04 1 16,348,024 32 0.92 14,339,855 32 1.12 17,636,208 32 1 15,699,407 32
BCG_0357C PUTATIVE GLYCEROPHOSPHORYL DIESTER PHOSPH 28319 4 4 0.91 2,280,258 4 1.09 2,717,779 4 1.04 1 2,497,824 4 1.25 3,008,626 4 1.04 2,503,610 4 1 2,404,472 4
BCG_1813 HYPOTHETICAL PROTEIN 20457 8 8 0.97 4,546,990 8 0.88 4,054,309 8 1.03 1 4,529,471 8 0.84 3,676,553 8 0.82 3,574,559 8 1 4,395,150 8
BCG_2360C PUTATIVE MOLYBDOPTERIN BIOSYNTHESIS PROTEIN 35271 2 2 1.38 1,333,566 2 1.19 1,151,208 2 1.03 1 965,136 2 1.25 1,170,462 2 1.08 1,016,318 2 1 937,547 2
BCG_2840C HYPOTHETICAL PROTEIN 25773 2 2 0.91 1,271,738 3 1.15 1,611,893 3 1.01 1 1,400,525 3 1 1,378,834 3 0.94 1,295,193 3 1 1,380,514 3
BCG_1681 50S RIBOSOMAL PROTEIN L35 RPMI 7220 3 2 1.31 2,564,481 6 1.68 3,277,588 6 1.01 1 1,955,825 6 1.53 2,955,155 6 1.09 2,104,019 6 1 1,930,688 6
BCG_0755 PUTATIVE 30S RIBOSOMAL PROTEIN S19 RPSS 10804 13 7 0.99 8,348,383 17 1.27 10,761,256 17 1.00 1 8,477,478 17 1.15 9,738,759 17 1.03 8,715,492 17 1 8,454,342 17
BCG_2962C PUTATIVE MULTIFUNCTIONAL MYCOCEROSIC ACID SY 224396 5 5 1.37 4,237,806 8 0.84 2,587,265 8 1.00 1 3,084,434 8 0.51 1,574,373 8 1.14 3,492,314 8 1 3,087,421 8
BCG_3453C HYPOTHETICAL PROTEIN 14317 3 2 0.96 626,270 3 1.05 689,672 3 0.99 1 654,493 3 1.07 706,042 3 1 658,738 3 1 659,899 3
BCG_3052C PUTATIVE ELECTRON TRANSFER FLAVOPROTEIN (BE 28081 2 2 2.25 1,224,570 3 1.04 565,385 3 0.99 1 543,515 3 0.75 411,708 3 1.25 688,152 3 1 551,441 3
BCG_0084 PUTATIVE 30S RIBOSOMAL PROTEIN S6 RPSF 10935 5 5 0.79 3,151,599 6 0.99 3,943,882 6 0.98 1 4,001,761 6 0.84 3,413,649 6 0.87 3,526,453 6 1 4,070,749 6
BCG_3252 PUTATIVE SHORT-CHAIN DEHYDROGENASE/REDUCTA 29814 2 2 1.39 1,657,685 2 1 1,185,846 2 0.98 1 1,190,836 2 0.94 1,141,262 2 1.27 1,545,314 2 1 1,212,874 2
BCG_2541C HYPOTHETICAL PROTEIN 8374 2 2 0.71 1,241,151 2 0.94 1,636,893 2 0.96 1 1,748,696 2 0.83 1,496,343 2 0.89 1,616,392 2 1 1,814,618 2
BCG_3863C PUTATIVE FATTY-ACID-COA LIGASE FADD32 69260 5 4 0.85 2,009,077 6 0.85 1,996,226 6 0.96 1 2,353,165 6 0.96 2,339,840 6 0.94 2,289,701 6 1 2,443,937 6
BCG_3523C PUTATIVE 30S RIBOSOMAL PROTEIN S4 RPSD 23476 29 21 1.08 18,149,619 38 1.08 18,165,715 38 0.96 1 16,804,360 38 1.12 19,532,495 38 0.89 15,584,058 38 1 17,461,998 38
BCG_0183 PUTATIVE ALDEHYDE DEHYDROGENASE (NAD+) DEPE 55035 6 6 1.07 4,146,828 9 1.68 6,535,578 9 0.96 1 3,863,441 9 1.64 6,615,281 9 1.51 6,103,857 9 1 4,028,901 9
BCG_2911C PUTATIVE 30S RIBOSOMAL PROTEIN S2 RPSB 31089 11 9 1.09 8,519,527 13 1.06 8,217,342 13 0.96 1 7,806,554 13 1.2 9,853,176 13 1.04 8,562,248 13 1 8,167,493 13
BCG_2235 PUTATIVE TRANSMEMBRANE PROTEIN 26830 8 7 1.39 5,726,577 9 1.78 7,229,363 9 0.95 1 4,107,477 9 1.87 8,012,363 9 1.4 5,942,780 9 1 4,342,837 9
BCG_1682 50S RIBOSOMAL PROTEIN L20 RPLT 14527 6 6 1.5 4,744,640 12 1.41 4,447,438 12 0.94 1 3,162,950 12 1.63 5,475,228 12 1.29 4,317,207 12 1 3,372,448 12
BCG_1324 HYPOTHETICAL PROTEIN 25230 2 2 0.9 442,469 3 0.79 388,482 3 0.93 1 489,736 3 0.94 498,504 3 0.89 467,879 3 1 528,125 3
BCG_0765 PUTATIVE 50S RIBOSOMAL PROTEIN L24 RPLX 11475 4 3 1.05 3,860,189 4 1.06 3,872,761 4 0.92 1 3,657,991 4 0.92 3,670,214 4 0.98 3,883,938 4 1 3,973,630 4
BCG_0767 PUTATIVE 30S RIBOSOMAL PROTEIN S14 RPSN1 6825 2 1 1.13 624,589 4 1.31 722,706 4 0.92 1 550,148 4 1.1 660,156 4 1.09 649,737 4 1 598,284 4
BCG_0717 DNA-DIRECTED RNA POLYMERASE (BETA' CHAIN) RPO 146710 45 40 1.31 34,582,153 61 1.02 26,909,725 61 0.90 1 26,470,689 61 1.02 29,786,012 61 1.19 34,888,297 61 1 29,299,144 61
BCG_0078C HYPOTHETICAL PROTEIN 20408 2 2 1.11 1,472,087 2 0.93 1,228,938 2 0.90 1 1,322,887 2 1.1 1,619,669 2 0.9 1,318,349 2 1 1,469,306 2
BCG_0391 PUTATIVE CHAPERONE PROTEIN DNAJ1 41315 3 3 0.6 904,448 7 0.87 1,309,512 7 0.89 1 1,508,886 7 0.57 967,202 7 0.7 1,185,596 7 1 1,692,749 7
BCG_0691C METHOXY MYCOLIC ACID SYNTHASE 4 MMAA4 34636 3 3 0.82 1,923,288 4 0.73 1,720,277 4 0.89 1 2,344,162 4 0.66 1,734,446 4 0.6 1,569,411 4 1 2,632,433 4
BCG_0734 PUTATIVE ELONGATION FACTOR TU TUF (EF-TU) 43594 5 4 1.66 3,198,519 6 1.02 1,983,955 6 0.88 1 1,945,674 6 0.86 1,885,606 6 1.32 2,912,550 6 1 2,202,899 6
BCG_2929C HYPOTHETICAL PROTEIN 8521 7 5 0.79 1,780,913 10 0.88 1,983,412 10 0.88 1 2,226,202 10 0.69 1,732,148 10 0.67 1,695,910 10 1 2,528,948 10
BCG_0504C HYPOTHETICAL PROTEIN 21305 3 3 0.73 979,834 4 0.73 973,608 4 0.88 1 1,340,437 4 0.7 1,070,754 4 0.7 1,075,850 4 1 1,530,202 4
BCG_2428 PUTATIVE 30S RIBOSOMAL PROTEIN S20 RPST 9405 8 7 1.58 11,464,267 9 1.56 11,328,324 9 0.86 1 7,198,387 9 1.19 9,990,740 9 1.13 9,462,682 9 1 8,383,780 9
BCG_2462C PUTATIVE 50S RIBOSOMAL PROTEIN L21 RPLU 11151 7 5 1 5,139,659 8 1.19 6,131,551 8 0.86 1 5,129,042 8 1.09 6,520,674 8 0.93 5,586,592 8 1 5,978,979 8
BCG_1595 PUTATIVE FATTY ACYL-COA REDUCTASE 36821 10 10 0.93 7,890,734 13 1.09 9,231,124 13 0.84 1 8,463,675 13 0.87 8,690,043 13 0.83 8,353,608 13 1 10,036,474 13
BCG_2305 PUTATIVE CDP-DIACYLGLYCEROL PYROPHOSPHATAS 28608 2 2 0.94 1,528,054 3 1.14 1,852,639 3 0.83 1 1,633,024 3 1.18 2,318,161 3 1.18 2,322,601 3 1 1,969,295 3
BCG_0573 HYPOTHETICAL PROTEIN 43055 2 2 0.75 585,472 4 0.77 601,372 4 0.82 1 779,967 4 0.69 653,145 4 0.74 701,244 4 1 946,402 4
BCG_2925C PUTATIVE 50S RIBOSOMAL PROTEIN L19 RPLS 13013 9 9 0.96 6,759,359 11 0.94 6,604,559 11 0.82 1 7,044,061 11 0.97 8,382,849 11 0.76 6,583,601 11 1 8,638,014 11
BCG_3010 PUTATIVE TRANSCRIPTIONAL REGULATORY PROTEIN 24316 11 10 0.92 3,978,100 14 0.96 4,133,943 14 0.81 1 4,327,570 14 1.01 5,411,983 14 0.84 4,504,670 14 1 5,362,156 14
BCG_3915 PUTATIVE HISTONE-LIKE PROTEIN HNS 13823 4 4 1.53 3,250,199 4 1.34 2,842,714 4 0.81 1 2,130,673 4 0.98 2,583,215 4 0.9 2,372,222 4 1 2,645,507 4
BCG_0835 HYPOTHETICAL PROTEIN 25052 2 2 0.89 824,679 3 1.14 1,050,445 3 0.80 1 924,486 3 0.75 865,636 3 0.68 788,838 3 1 1,154,909 3
BCG_3007C PUTATIVE DNA-BINDING PROTEIN HU HOMOLOG HUP 21292 12 11 1.13 12,376,605 15 1.13 12,377,556 15 0.80 1 11,035,752 15 0.54 7,315,332 15 1.26 17,173,003 15 1 13,840,170 15
BCG_3526C PUTATIVE 50S RIBOSOMAL PROTEIN L36 RPMJ 4343 2 2 0.74 1,124,603 3 0.92 1,400,833 3 0.79 1 1,518,340 3 0.65 1,251,885 3 0.6 1,161,730 3 1 1,920,284 3
BCG_3509C PUTATIVE 50S RIBOSOMAL PROTEIN L13 RPLM 16337 5 5 0.94 3,036,712 7 1.05 3,377,329 7 0.79 1 3,253,703 7 0.79 3,267,399 7 0.87 3,594,451 7 1 4,128,536 7
BCG_3878C PUTATIVE ACYLTRANSFERASE 28454 4 4 0.97 2,952,341 4 1.12 3,405,096 4 0.79 1 3,048,064 4 0.86 3,337,813 4 0.83 3,215,575 4 1 3,874,980 4
BCG_3487C 60 KDA CHAPERONIN 1 GROEL1 55877 5 5 1.19 4,389,211 7 0.96 3,562,371 7 0.78 1 3,704,160 7 0.58 2,756,237 7 1.02 4,834,698 7 1 4,722,366 7
BCG_2803C PUTATIVE 30S RIBOSOMAL PROTEIN S15 RPSO 10475 4 4 0.96 2,869,586 5 1.15 3,421,560 5 0.77 1 2,981,864 5 0.71 2,753,425 5 0.9 3,462,667 5 1 3,866,898 5
BCG_2862C HYPOTHETICAL PROTEIN 19565 5 5 1.02 3,600,629 6 1.26 4,479,819 6 0.76 1 3,531,190 6 1.13 5,239,702 6 0.95 4,382,316 6 1 4,631,432 6
BCG_3488C 10 KDA CHAPERONIN GROES 10804 4 4 1.43 1,433,949 7 6.73 6,734,580 7 0.74 1 1,001,070 7 1.46 1,962,296 7 1.04 1,401,033 7 1 1,348,917 7
BCG_3270C HYPOTHETICAL PROTEIN 24567 6 6 1.1 5,525,830 6 1.1 5,533,242 6 0.74 1 5,061,741 6 1.16 7,971,083 6 0.95 6,547,180 6 1 6,873,364 6
BCG_0764 PUTATIVE 50S RIBOSOMAL PROTEIN L14 RPLN 13428 5 5 1.15 4,734,734 9 1.1 4,546,263 9 0.73 1 4,132,696 9 0.95 5,384,834 9 0.85 4,827,127 9 1 5,673,893 9
BCG_0752 PUTATIVE 50S RIBOSOMAL PROTEIN L4 RPLD 23743 10 9 1.26 9,508,073 12 1.32 10,018,038 12 0.72 1 7,508,987 12 0.83 8,564,528 12 0.98 10,243,649 12 1 10,418,954 12
BCG_3727 PUTATIVE TRANSMEMBRANE PROTEIN 18919 3 3 1.28 716,477 3 1.2 671,182 3 0.72 1 558,628 3 1.21 937,759 3 1.08 842,475 3 1 777,574 3
BCG_2243 HYPOTHETICAL PROTEIN 56332 3 3 1.17 1,306,009 6 1.16 1,297,125 6 0.70 1 1,119,628 6 1.26 2,028,633 6 1.12 1,797,137 6 1 1,608,849 6
BCG_0479 60 KDA CHAPERONIN 2 GROEL2 56727 23 20 2.3 34,886,269 29 1.4 21,269,569 29 0.69 1 15,192,740 29 0.72 15,945,987 29 1.56 34,444,710 29 1 21,996,057 29
BCG_0027C PUTATIVE TRANSMEMBRANE PROTEIN 40944 2 2 1.4 1,366,098 3 1.49 1,450,130 3 0.68 1 974,671 3 1.17 1,688,605 3 1.02 1,465,252 3 1 1,443,710 3
BCG_2649 PUTATIVE METHYLTRANSFERASE 29542 6 6 0.86 3,696,850 11 1.01 4,298,886 11 0.67 1 4,289,676 11 0.76 4,833,424 11 0.58 3,672,613 11 1 6,438,136 11
BCG_0861 PUTATIVE PHOSPHORIBOSYLFORMYLGLYCINAMIDINE 38393 2 2 0.86 760,109 2 0.87 767,784 2 0.66 1 884,890 2 0.81 1,078,233 2 0.98 1,313,762 2 1 1,339,602 2
BCG_1504C HYPOTHETICAL PROTEIN 18316 2 2 0.85 1,106,654 2 0.94 1,223,425 2 0.64 1 1,296,072 2 0.63 1,259,979 2 0.51 1,028,788 2 1 2,011,858 2
BCG_3127C PUTATIVE CELL DIVISION ATP-BINDING PROTEIN FTSE 25596 5 5 0.83 1,945,879 10 1.07 2,511,679 10 0.64 1 2,357,143 10 0.72 2,666,550 10 0.81 2,980,963 10 1 3,705,012 10
BCG_1951C PUTATIVE OXIDOREDUCTASE FADB5 35755 4 4 0.87 2,582,983 4 0.9 2,676,188 4 0.64 1 2,979,720 4 0.67 3,163,053 4 0.79 3,702,759 4 1 4,692,271 4
BCG_2958 PUTATIVE DAUNORUBICIN-DIM-TRANSPORT ATP-BIND 35796 3 3 1.15 1,312,545 3 1.59 1,811,253 3 0.63 1 1,136,130 3 1.1 1,968,305 3 0.95 1,711,695 3 1 1,795,083 3
BCG_0750 30S RIBOSOMAL PROTEIN S10 RPSJ (TRANSCRIPTION 11431 7 6 0.97 4,810,428 9 0.91 4,534,791 9 0.62 1 4,991,378 9 0.65 5,299,195 9 0.64 5,149,920 9 1 8,074,586 9
BCG_0121 HYPOTHETICAL PROTEIN 24649 2 2 0.83 967,831 4 1.37 1,601,897 4 0.62 1 1,166,566 4 0.68 1,292,296 4 0.7 1,322,451 4 1 1,895,484 4
BCG_3978C HYPOTHETICAL PROTEIN SIMILAR TO JAG PROTEIN 20589 4 3 0.94 1,932,475 4 0.82 1,684,790 4 0.61 1 2,050,882 4 0.59 1,957,373 4 0.78 2,601,765 4 1 3,338,335 4
BCG_0772 PUTATIVE 50S RIBOSOMAL PROTEIN L30 RPMD 7347 2 2 0.93 908,081 3 0.86 840,822 3 0.61 1 975,386 3 0.56 895,607 3 0.52 830,897 3 1 1,591,185 3
BCG_1680 PUTATIVE INITIATION FACTOR IF-3 INFC 22349 3 3 0.89 1,180,326 5 1.2 1,602,971 5 0.61 1 1,331,702 5 0.75 1,641,216 5 0.75 1,628,107 5 1 2,176,508 5
BCG_0280C PUTATIVE 3-OXOACYL-ACYL-CARRIER PROTEIN] RED 46830 5 4 1.28 3,227,141 8 1.26 3,186,302 8 0.60 1 2,506,473 8 0.78 3,237,257 8 1 4,169,147 8 1 4,153,488 8
BCG_1890C PUTATIVE NADH DEHYDROGENASE NDH 49718 3 3 1.38 2,629,029 4 1.67 3,194,113 4 0.60 1 1,907,776 4 1.05 3,341,014 4 0.88 2,809,656 4 1 3,192,803 4
BCG_3876C PUTATIVE ACYLTRANSFERASE 29291 4 4 1.1 3,697,610 6 1.04 3,488,150 6 0.59 1 3,351,119 6 0.82 4,646,203 6 0.84 4,783,091 6 1 5,700,220 6
BCG_3269C PUTATIVE PREPROTEIN TRANSLOCASE SUBUNIT 1 SE 106022 3 3 1.05 1,396,371 5 1.06 1,411,621 5 0.59 1 1,326,419 5 0.85 1,925,390 5 0.86 1,939,686 5 1 2,265,989 5
BCG_1179C HYPOTHETICAL PROTEIN 32190 2 2 1 552,992 3 1.1 603,883 3 0.58 1 550,646 3 0.65 614,718 3 0.54 511,515 3 1 943,630 3
BCG_0771 PUTATIVE 30S RIBOSOMAL PROTEIN S5 RPSE 22888 6 6 1.65 2,859,676 9 2.41 4,156,281 9 0.58 1 1,750,805 9 1.18 3,581,093 9 1.11 3,365,213 9 1 3,032,802 9
BCG_2974 HYPOTHETICAL PROTEIN 45104 4 3 1.19 1,403,035 5 0.84 994,895 5 0.54 1 1,178,584 5 0.53 1,145,372 5 0.57 1,243,356 5 1 2,167,756 5
BCG_1908C PUTATIVE L-LACTATE DEHYDROGENASE (CYTOCHRO 45328 9 9 1.07 4,502,537 10 1.73 7,237,541 10 0.53 1 4,145,299 10 0.98 7,567,122 10 1.32 10,275,346 10 1 7,792,973 10
BCG_3913 HYPOTHETICAL PROTEIN 23811 5 5 1.13 3,408,373 9 1.57 4,733,018 9 0.52 1 3,023,360 9 0.84 4,825,267 9 1.24 7,130,497 9 1 5,767,262 9
BCG_2973 PUTATIVE METHYLTRANSFERASE 30652 3 3 0.95 978,829 6 0.91 941,367 6 0.51 1 1,036,669 6 0.73 1,480,241 6 0.64 1,290,752 6 1 2,032,832 6
BCG_3662C PUTATIVE LSR2 PROTEIN PRECURSOR 12098 7 5 1.31 2,573,265 10 1.08 2,134,221 10 0.50 1 1,967,415 10 0.95 3,767,984 10 1.2 4,777,720 10 1 3,948,870 10
BCG_0086 PUTATIVE 30S RIBOSOMAL PROTEIN S18-1 RPSR1 9543 14 11 1.35 8,195,270 16 1.89 11,282,673 16 0.46 1 6,001,012 16 0.84 10,875,689 16 0.99 12,977,724 16 1 13,159,809 16
HA-UBIQUITIN HA-Ubiquitin 21912 2 2 2.12 3,434,181 2 1.22 1,983,173 2 0.45 1 1,619,674 2 0.61 2,206,831 2 0.72 2,569,189 2 1 3,595,275 2
BCG_0756 PUTATIVE 50S RIBOSOMAL PROTEIN L22 RPLV 20380 3 3 3.11 3,556,369 3 3.25 3,711,455 3 0.37 1 1,143,427 3 0.96 2,930,862 3 1.22 3,749,139 3 1 3,062,827 3
BCG_0087 PUTATIVE 50S RIBOSOMAL PROTEIN L9 RPLI 16170 3 3 1.11 1,902,294 3 0.75 1,283,335 3 0.36 1 1,707,307 3 0.49 2,321,494 3 0.72 3,436,850 3 1 4,754,484 3
BCG_0683 PUTATIVE 50S RIBOSOMAL PROTEIN L33 RPMG2 6496 3 2 1.04 2,825,605 3 0.98 2,653,806 3 0.36 1 2,713,552 3 0.45 3,433,231 3 0.53 4,039,461 3 1 7,567,669 3
BCG_0813C PUTATIVE ZINC-CONTAINING ALCOHOL DEHYDROGEN 39748 2 1 1.12 256,878 2 0.83 190,942 2 0.21 1 229,802 2 1.06 1,144,450 2 1.07 1,150,563 2 1 1,078,172 2
sample 5
immobilized cpd: GSK730, 2mM
competing cpd: GSK730 100 µM
sample 6
immobilized cpd: GSK730, 2mM
competing cpd: none
sample 1
immobilized cpd: GSK729, 2mM
competing cpd:  GSK729 100 µM
sample 3
immobilized cpd: GSK729, 2mM
competing cpd: none
sample 2
immobilized cpd: GSK729, 2mM
competing cpd: GSK730, 100 µM
sample 4
immobilized cpd: GSK730, 2mM
competing cpd: GSK729, 100 µM
184_2_supp_3471_nv4kr6
1Supplementary Table 3: 
6-plexed Chemoproteomics Experiment #3
Name Protein description MW no_of_Quant. Spectra no_of_Quant. Uniq. 
Peptides
IC50 (µM) Hill Slope
BCG_0957 PUTATIVE ENOYL-COA HYDRATASE ECHA6 26029 73 21 1.81 0.93
BCG_0023C PUTATIVE CHROMOSOME PARTITIONING PROT 37018 2 2 >30
BCG_0027C PUTATIVE TRANSMEMBRANE PROTEIN 40944 2 2 >30
BCG_0050C HYPOTHETICAL PROTEIN TB39 8 56003 2 2 >30
BCG_0085 PUTATIVE SINGLE-STRAND BINDING PROTEIN S 17353 38 7 >30
BCG_0086 PUTATIVE 30S RIBOSOMAL PROTEIN S18-1 RPS 9543 4 3 >30
BCG_0389 PUTATIVE CHAPERONE PROTEIN DNAK 66831 6 6 >30
BCG_0437C PUTATIVE ACYL-COA DEHYDROGENASE FADE7 42297 4 4 >30
BCG_0479 60 KDA CHAPERONIN 2 GROEL2 56727 12 12 >30
BCG_0504C HYPOTHETICAL PROTEIN 21305 3 3 >30
BCG_0516 HEPARIN BINDING HEMAGGLUTININ HBHA 21534 10 9 >30
BCG_0573 HYPOTHETICAL PROTEIN 43055 3 3 >30
BCG_0590C HYPOTHETICAL PROTEIN 14346 2 2 >30
BCG_0691C METHOXY MYCOLIC ACID SYNTHASE 4 MMAA4 34636 3 3 >30
BCG_0716 DNA-DIRECTED RNA POLYMERASE SUBUNIT BE 129236 18 14 >30
BCG_0717 DNA-DIRECTED RNA POLYMERASE (BETA' CHAI 146710 16 16 >30
BCG_0734 PUTATIVE ELONGATION FACTOR TU TUF (EF-TU 43594 6 5 >30
BCG_0750 30S RIBOSOMAL PROTEIN S10 RPSJ (TRANSCRI 11431 4 4 >30
BCG_0755 PUTATIVE 30S RIBOSOMAL PROTEIN S19 RPSS 10804 2 1 >30
BCG_0757 PUTATIVE 30S RIBOSOMAL PROTEIN S3 RPSC 30020 9 8 >30
BCG_0767 PUTATIVE 30S RIBOSOMAL PROTEIN S14 RPSN1 6825 2 1 >30
BCG_0770 PUTATIVE 50S RIBOSOMAL PROTEIN L18 RPLR 13184 3 3 >30
BCG_0780 HYPOTHETICAL PROTEIN 25980 5 5 >30
BCG_0956C PUTATIVE ACETYL-COENZYME A CARBOXYLASE 51772 9 9 >30
BCG_0963 HYPOTHETICAL PROTEIN 27627 3 3 >30
BCG_1463 PUTATIVE PRIMOSOMAL PROTEIN N' PRIA 69839 4 4 >30
BCG_1472C PUTATIVE LIPOPROTEIN LPRG 24548 2 2 >30
BCG_1595 PUTATIVE FATTY ACYL-COA REDUCTASE 36821 7 7 >30
BCG_1668 PUTATIVE RIBOSOMAL PROTEIN S1 RPSA 53232 4 4 >30
BCG_1676 EXCINUCLEASE ABC, SUBUNIT A UVRA 106132 4 4 >30
BCG_1798 PUTATIVE CUTINASE CUT1 21999 2 1 >30
BCG_1812C HYPOTHETICAL INTEGRAL MEMBRANE PROTEIN 63512 12 12 >30
BCG_2142 HYPOTHETICAL PROTEIN 31871 9 6 >30
BCG_2299 PUTATIVE ESTERASE LIPM 46681 2 2 >30
BCG_2314 HYPOTHETICAL PROTEIN 34986 2 2 >30
BCG_2447 ALKYL HYDROPEROXIDE REDUCTASE C PROTE 21566 7 6 >30
BCG_2607C ADENINE PHOSPHORIBOSYLTRANSFERASE APT 23246 2 2 >30
BCG_2616C PUTATIVE HOLLIDAY JUNCTION DNA HELICASE 20189 7 7 >30
BCG_2724 IRON-DEPENDENT REPRESSOR AND ACTIVATO 25233 2 2 >30
BCG_2767 HYPOTHETICAL PROTEIN 33610 2 2 >30
BCG_2801C BIFUNCTIONAL PROTEIN POLYRIBONUCLEOTID 79735 18 16 >30
BCG_2859C PUTATIVE TRANSLATION INITIATION FACTOR IF 94041 3 3 >30
BCG_2925C PUTATIVE 50S RIBOSOMAL PROTEIN L19 RPLS 13013 2 2 >30
BCG_3007C PUTATIVE DNA-BINDING PROTEIN HU HOMOLOG 21292 6 5 >30
BCG_3008C PUTATIVE 3-ISOPROPYLMALATE DEHYDRATASE 21780 2 2 >30
BCG_3009C PUTATIVE 3-ISOPROPYLMALATE DEHYDRATASE 50199 4 4 >30
BCG_3142 PUTATIVE THIOSULFATE SULFURTRANSFERASE 35999 4 4 >30
BCG_3222C PUTATIVE DNA HELICASE II HOMOLOG UVRD2 75604 14 13 >30
BCG_3277C PUTATIVE ADENOSYLHOMOCYSTEINASE SAHH 54324 3 3 >30
BCG_3487C 60 KDA CHAPERONIN 1 GROEL1 55877 2 2 >30
BCG_3488C 10 KDA CHAPERONIN GROES 10804 2 2 >30
BCG_3521C PUTATIVE 50S RIBOSOMAL PROTEIN L17 RPLQ 19475 2 2 >30
BCG_3522C PUTATIVE DNA-DIRECTED RNA POLYMERASE (A 37706 9 8 >30
BCG_3523C PUTATIVE 30S RIBOSOMAL PROTEIN S4 RPSD 23476 8 8 >30
BCG_3524C PUTATIVE 30S RIBOSOMAL PROTEIN S11 RPSK 14771 6 5 >30
BCG_3662C PUTATIVE LSR2 PROTEIN PRECURSOR 12098 4 4 >30
BCG_3704C DNA TOPOISOMERASE I TOPA 102370 45 40 >30
BCG_3743 PUTATIVE LYASE 37641 2 2 >30
BCG_3863C PUTATIVE FATTY-ACID-COA LIGASE FADD32 69260 5 5 >30
BCG_3904 PUTATIVE BACTERIOFERRITIN BFRB 20442 2 2 >30
BCG_3915 PUTATIVE HISTONE-LIKE PROTEIN HNS 13823 3 3 >30
184_2_supp_3472_nv47t1
 Ligand Kd (µM)  Bmax R2 
C4-CoA 10.4 ± 2.4  3476 ± 175 0.921 
C12-CoA 3.0 ± 1.1  2759 ± 135 0.87 
C14-CoA 3.1 ± 0.9  2916 ± 97 0.935 
C16-CoA 2.8 ± 1.4  2321 ± 136 0.819 
C18-CoA 1.4 ± 1.3  2971 ± 203 0.777 
C20-CoA 3.5 ± 0.4  2222 ± 199 0.671 
GSK951A 0.45 ± 0.06  169 ± 2 0.957 
GSK366A 5.6 ± 0.9  1947 ± 108 0.954 
GSK059A 9.6 ± 1.9  2653 ± 240 0.937 
GSK572A 1.9 ± 0.6  2506 ± 156 0.837 
GSK573A 285.8 ± 68.9  21827 ± 4074 0.980 
Competition C20-CoA 
with GSK951A  
Fold increase 
of Kd relative 
to no drug 
  
0.25 µM drug 2.6 ± 0.9 0.7 2278 ± 104 0.92 
2.5 µM drug 13.6 ± 2.1 3.8 994 ± 52 0.968 
10 µM drug 10.2 ± 5.5 2.9 917 ± 144 0.709 
Competition C4-CoA 
with GSK951A     
0.25 µM drug 8.9 ± 2.7 0.86 4665 ± 381 0.887 
2.5 µM drug 23.1 ± 2.8 2.2 3154 ± 162 0.985 
10 µM drug N.D. - N.D.  
Binding of point mutant     
EchA6W133A + GSK951A N.D. - N.D.  
EchA6W133A + C20-CoA 141.7 ± 15.3 - 1196 ± 67 0.951 
N.D. – not determined due to failure of non-linear fitting.  
 
X-ray diffraction data        
 apo EchA6  EchA6:C20-CoA EchA6:GSK366  EchA6:GSK059 EchA6:GSK572  EchA6:GSK951 EchA6:GSK729 
PDB accession code 5DTP 5DTW 5DU4 5DU6 5DU8 5DUC 5DUF 
X-ray source Diamond I04 Diamond I03 Diamond I04-1 Diamond I03 Diamond I03 In-house Diamond I04-1 
Wavelength (Å) 0.9795 0.9763 0.92 0.9763 0.9762 1.5414 0.92 
Space group P3221 P21 H3 P212121 P212121 P212121 P63 
Cell parameters a,b,c (Å) 103.1, 103.1, 
143.4 
113.7, 51.4, 156.9, 
β = 106.7º 
94.83, 94.83, 
87.51 
51.4, 116.6, 
171.8 
51.4, 116, 171.5 51.4,  119.2,  
171.6 
103.9, 103.9, 
54.4 
Molecules in asymmetric unit 3 6 1 3 3 3 1 
Resolution (last shell) (Å) 89.3 - 1.91  
(1.96 - 1.91) 
108.9 - 2.4  
(2.46 - 2.40) 
47.4 - 1.7  
(1.75 - 1.70) 
85.9 - 2.61  
(2.68 - 2.61) 
96.1 - 2.23  
(2.29 - 2.23) 
48.9 - 2.7  
(2.85 - 2.70) 
51.9 - 1.43  
(1.47 - 1.43) 
Rmerge (%)1) 6.5 (70.4) 8.4 (49.9) 6.4 (53.0) 10.5 (59.2) 9.4 (67.4) 9.8 (35.9) 4.5 (67.5) 
Total/unique observations 505752 / 68929 246225 / 68420 175974 / 31804 135533 / 31967 322214 / 50922 338678 / 29564 696415 / 61860 
I/σ(I) 1) 15.9 (2.7) 9.6 (2.1) 12.6 (2.7) 8.7 (2.0) 11.9 (2.9) 25.8 (7.3) 26.2 (3.5) 
Completeness (%)1) 100 (100) 99.4 (99.5) 98.9 (99.3) 99.0 (99.4) 99.9 (99.8) 99.6 (97.5) 100 (99.9) 
Multiplicity1) 7.3 (7.4) 3.6 (3.3) 5.5 (5.7) 4.2 (4.3) 6.3 (6.2) 11.5 (11.1) 11.3 (11.1) 
        
Refinement        
Resolution range 89.3 - 1.91 108.93 - 2.4 47.4 - 1.7 85.9 - 2.6 96.07 - 2.23 48.9 - 2.7 51.9 – 1.50 
Unique reflections 65376 64285 31794 31907 48273 29498 53631 
Rcryst / Rfree (%) 18.2 / 20.1 23.7 / 27.6 19.3 / 21.5 19.3 / 24.0 21.9 / 25.4 18.7 / 23.4 17.3 / 18.4 
No of non-hydogen atoms 5610 11052 1927 5608 5606 5729 2096 
Protein / Ligand / Solvent 5284 / - / 326 10793 / 138 / 121 1800 / 33 / 94 5419 / 87 / 102 5344 / 96 / 163 5452 / 168 / 109 1801 / 24 / 271 
RMSD bonds / angles (Å / º) 0.006 / 0.976 0.009 / 1.24 0.006  / 1.2 0.009  / 1.13 0.009 / 1.38 0.009 / 1.38 0.006 / 1.14 
Wilson B-factor (Å2) 28.4 32.9 30 40.2 31.6 41.6 19.1 
Overall average B-factor (Å2) 32.5 31.1 34.5 47.8 40.4 27.6 23.2 
Protein / Ligand / Solvent (Å2) 32.5 / - / 33.5 31.2 / 35.4 / 24.2 34.7 / 34.8 / 31.5 47.9 / 49.2 / 
36.1 
40.4 / 38.5 / 
39.7 
26.7 / 56.6 / 23.7 21.7 / 20.6 / 
33.4 
RMSD B-factors (Å2) 0.95 4.4 1.3 3.2 1.4 3.3 1.9 
Ramachandran plot2) 
Favoured / allowed / disallowed 
(%) 
97.4 / 2.5/ 0.1 96.7 / 3.6 / 0.1 97.1 / 2.9 / 0 95.8 / 4.0 / 0.2 96.9 / 3.0 / 0.1 95.6 / 4.4 / 0.0 97.9 / 2.1 / 0 
1)Values in parentheses refer to the high resolution shell. 2) The Ramachandran plot distribution was calculated using Molprobity. 
 
    
  M. tuberculosis H37Rv M. bovis BCG M. smegmatis M. marinum M. leprae 
  % seq id Accession % seq id Accession % seq id Accession % seq id Accession % seq id Accession 
EchA6 100 CCP43653.1 100 NP_854586.1 74 YP_889873.1 74 EPQ74024.1 86 NP_302400.1 
EchA11) 100 CAB06989.1 -  66 YP_886579.1 92 YP_001848785.1 -  
EchA2 100 CAB09570.1 100 NP_854127.1 -  91 WP_020731738.1 -  
EchA3 100 CAB07121.1 100 NP_854307.1 56 YP_885721.1 85 EPQ73703.1 -  
EchA4 100 CAA17470.1 100 NP_854350.1 90 YP_885774.1 93 YP_001849314.1 -  
EchA5 100 CCP43418.1 100 P_854352.1 82 YP_885776.1 89 WP_020731927.1 -  
            
EchA7 100 CCP43720.1 100 NP_854653.1 72 YP_889733.1 83 EPQ74105.1 -  
EchA81) 100 CCP43821.1 100 NP_854754.1 82 YP_889523.1 91 YP_001852658.1 86 NP_302555.1 
EchA9 100 CCP43822.1 100 NP_854755.1 68 YP_889522.1 83 WP_020729788.1 78 NP_302554.1 
EchA10 100 CCP43897.1 100 NP_854830.1 64 YP_889431.1 70 YP_001852570.1 -  
EchA11 100 CCP43896.1 100 NP_854829.1 61 YP_889431.1 61 WP_020729866.1 -  
EchA12 100 CCP44231.1 99 NP_855159.1 82 YP_006567817.1 90 WP_020724991.1 72 NP_301896.1 
EchA13 100 CCP44702.1 100 NP_855620.1 62 YP_006570456.1 86 YP_001851158.1 - - 
EchA14 100 CCP45280.1 100 NP_856158.1 75 YP_888969.1 43 YP_001852883.1 -  
EchA15 100 CCP45477.1 100 NP_856344.1 33 YP_889854.1 88 YP_001850341.1 -  
EchA16 100 CCP45632.1 100 YP_978935.1 81 YP_886978.1 90 YP_001850207.1 -  
EchA17 100 CCP45848.1 100 NP_856710.1 67 YP_885445.1 82 WP_020724610.1 86 NP_302187.1 
EchA18 100 CCP46194.1 100 NP_857049.1 -  -  -  
EchA191) 100 CCP46338.1 99 NP_857184.1 84 YP_890141.1 91 YP_001853261.1 -  
EchA20 100 CCP46372.1 100 NP_857219.1 88 YP_890227.1 94 WP_020730809.1 -  
EchA211) 100 CCP46603.1 100 NP_857440.1 80 YP_890568.1 90 YP_001853588.1 88 NP_301216.1 
1) EchA paralogues with conserved catalytic carboxylates required for enoyl-CoA hydratases activity are in bold. 
 
 Genes Primer Sequence (5’-3’) Restriction 
site 
EchA6 F_28a CATGCATGCATATGATCGGTATCACCCAGGCAGA NdeI 
EchA6 R_28a CATGCATGAAGCTTTTAAGCCCCTTGGAACTTCG HindIII 
TH_EchA6 F CATGCATGTCTAGAAATGATCGGTATCACCCAGGC XbaI 
TH_EchA6 R CATGCATGGGATCCTCAGCCCCTTGGAACTTCG BamHI 
TH_FabH F ACTCTAGAGATGACGGAGATCGCCACGACC XbaI 
TH_FabH R ATACGGTACCCGACCCTTCGGCATTCGCACCAC KpnI 
TH_KasA F ACTCTAGAGGTGAGTCAGCCTTCCACCGC XbaI 
TH_KasA R ATACGGTACCCGGTAACGCCCGAAGGCAAG KpnI 
TH_KasB F ACTCTAGAGGTGGGGGTCCCCCCGCTTGC XbaI 
TH_KasB R ATACGGTACCCGGTACCGTCCGAAGGCGATTGC KpnI 
TH_InhA F ACTCTAGAGATGACAGGACTGCTGGAC XbaI 
TH_InhA R ATACGGTACCCGGAGCAATTGGGTGTGCGC KpnI 
TH_MabA F ACTCTAGAGGTGACTGCCACAGCCAC XbaI 
TH_MabA R ATACGGTACCCGGTGGCCCATACCCATGCC KpnI 
TH_HadA F ACTCTAGAGGTGGCGTTGAGCGCAGAC XbaI 
TH_HadA R ATACGGTACCCGCGCAGCGCCATCAGAAAATCC KpnI 
TH_HadB F ACTCTAGAGATGGCGCTGCGTGAGTTC XbaI 
TH_HadB R ATACGGTACCCGCGCTAACTTCGCCGAGGC KpnI 
TH_HadC F ACTCTAGAGATGGCGCTCAAGACCGATATC XbaI 
TH_HadC R TAC CCG GGG CGC GGT CCT GAT GAC CTG CCC SmaI 
BCG_0957_LL TTTTTTTTCCATAAATTGGTCCCATGCCGCCGTAGATTCTC Van91I 
BCG_0957_LR TTTTTTTTCCATTTCTTGGTCCAGGGCCAGACCGTATTTCG Van91I 
BCG_0957_RL TTTTTTTTCCATAGATTGGTCAACGACGACGGCGCTATC Van91I 
BCG_0957_RR TTTTTTTTCCATCTTTTGGTCAGGAACCGTCCCGAGAAG Van91I 
mdRv0905_F GATCGATCAAGCTTATGATCGGTATCACCCAGGC HindIII 
mdRv0905_R GATCGATCATCGATTTAAGCCCCTTGGAACTTCG ClaI 
EchA6 F_pVV16 CATGCATGCATATGATCGGTATCACCCAGGCAGA NdeI 
EchA6 R_pVV16 CATGCATGAAGCTTAGCCCCTTGGAACTTCGGCG HindIII 
EchA6 
F_pMV261 
GATCGATCTGGCCAAGATGATCGGTATCACCCAGGC MscI 
EchA6 
R_pMV261 
GATCGATCAAGCTTTTAAGCCCCTTGGAACTTCG HindIII 
MmpL3 
F_pMV261 
GGCTGGAATTCATGTTCGCCTGGTGGGGTCG EcoRI 
MmpL3 
R_pMV261 
GGCAAGCTTTTAAAGGCGTCCTTCGCGGC HindIII 
EchA6W133A 
F_SDM 
GCCCTGGATAACGCGAGCATCCGCCG - 
EchA6W133A 
R_SDM 
CGGCGGATGCTCGCGTTATCCAGGGC - 
	  
